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ABSTRACT 
Immunoinformatics tools have multiple applications in human immunology research. One of 
their most prominent applications is the prediction of T cell epitopes to accelerate vaccine development. 
T cell epitopes are short peptides derived from pathogens that are recognized by the cells of the immune 
system (T cells) when presented on the surface of cells bound to a major histocompatibility complex 
(MHC) molecule, which results in a specific immune response. For their role as key drivers of the 
immune response, numerous algorithms have been developed to predict binding of peptides to MHC 
molecules; however, comparable tools are limited for other species. The goal of this thesis is to develop 
immunoinformatics tools for swine to aid in the design of vaccines for pathogens affecting the pork 
industry. One of the main reasons for the limited development of T cell epitope mapping tools for swine 
is the lack of data required to train and test the predictive algorithms. Through this research, we have 
developed PigMatrix, a tool for prediction of peptide binding to swine MHC molecules. In an initial 
analysis, PigMatrix predictive performance was favorable, in particular because its development did not 
require training data. Using PigMatrix, we have identified immunogenic peptides conserved in seven 
different strains of influenza A virus (IAV), a highly diverse virus that has a significant impact not only 
on swine, but also for humans. Protective potential of IAV vaccines is commonly predicted using 
genetic data and antibody cross-reactivity properties of the hemagglutinin (HA) surface protein, the 
most variable antigen and primary target of the antibody immune response. However, protection has 
been reported in the absence of cross-reactive antibodies to HA. To explore the role of T cell epitopes in 
vaccine protection, we have developed a method (EpiCC) to compare T cell epitope content between 
proteins. We found that the relationship of predicted T cell epitopes between HA sequences of a swine 
IAV inactivated vaccine and challenge strains was associated with protection, providing evidence that T 
cells contribute to vaccine efficacy. This approach may complement current methods for selection of 
influenza vaccines against novel viruses and influenza strains for vaccine development. Taken together, 
these findings demonstrate the potential of immunoinformatics tools for the development and 
evaluation of swine vaccines and will allow for further research to improve the tools and apply them to 
design novel vaccine candidates.  
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PREFACE 
The following dissertation has been prepared in manuscript format according to the guidelines 
of the Graduate School of the University of Rhode Island. The dissertation includes five chapters: 
Chapter 1, Introduction. Chapter 2, “Development and validation of an epitope prediction tool for swine 
(PigMatrix) based on the pocket profile method”, was published in BMC Bioinformatics. Chapter 3, “In 
vivo validation of predicted and conserved T cell epitopes in a swine Influenza model” was published in 
PLoS ONE. Chapter 4, “T cell epitope Content Comparison (EpiCC) of swine H1 influenza A virus 
hemagglutinin” was prepared for submission to Influenza and Other Respiratory Viruses. Chapter 5, 
Conclusions. 
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CHAPTER 1 
Introduction	
Immunoinformatics, also known as computational immunology, is a branch of bioinformatics 
that applies computational methods for both basic and translational immunology and vaccine research. 
One of the most common applications of immunoinformatics is the prediction of T cell epitopes. T cell 
epitopes are short linear peptides derived from pathogen proteins (or self proteins) that are recognizable 
by cells of the immune system (T lymphocytes or T cells) and induce a specific adaptive T cell-
mediated immune response (CMI) [1,2]. They are recognized by specialized antigen receptors on T 
cells, T cell receptors (TCRs); however, TCRs only recognize peptides if they are bound to major 
histocompatibility complex (MHC) molecules and presented on the surface of cells [2,3]. Due to the 
key role of T cells in the adaptive immune response against pathogens, numerous immunoinformatics 
tools have been developed to predict human T cell epitopes [4]. However, similar tools are limited for 
animals such as swine, cattle, and other important livestock. 
 
MHC molecules  
There are two classes of MHC molecules that interact with peptides; MHC class I and MHC class II [3]. 
These molecules are involved in different antigen presentation pathways and play different roles in the 
immune response to pathogens [2,3]. 
MHC Class I 
MHC class I molecules are expressed by all nucleated cells and generally present peptides derived from 
intracellular proteins of self and non-self origin [3]. The proteins are initially degraded into peptides by 
the proteasome and translocated into the endoplasmic reticulum (ER) by the transporter associated with 
antigen processing (TAP) [3,5]. Suitable peptides bind semi-folded MHC class I molecules anchored in 
the ER, and induce further folding facilitated by the peptide-loading complex [3,5,6]. Peptide-MHC 
complexes are then transported to the cell surface where they are presented to CD8 T cells circulating in 
the lymphatic system [3]. Upon TCR recognition of foreign peptides and binding of the T cell surface 
co-receptor CD8 to a second constant site on MHC class I, mature naïve CD8 T cells become activated 
and differentiate into cytotoxic effector CD8 T cells (cytotoxic T lymphocytes or CTL) [7]. CTL leave 
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the lymphoid tissue in high numbers and migrate to infected tissue [8]. The major roles of CTL are to 
(1) eliminate infected target cells by inducing apoptosis through release of cytotoxic proteins (perforins, 
granzymes) or expressing Fas ligand that binds to Fas on target cells, and (2) secrete cytokines (IFNγ, 
TNF-α and TNF-β), which contribute to host defense [2]. Once the infection is cleared, most of the CTL 
die, but a minor subset survive and become memory CD8 T cells. These cells are capable of responding 
rapidly to any subsequent similar infection [7].  
MHC Class II 
MHC class II molecules are expressed on professional antigen presenting cells (APC) and generally 
present peptides derived from extracellular proteins [2,3,9]. The proteins are first taken into the cell by 
phagocytosis or endocytosis, after which endocytic vesicles become acidified, fuse with lysosomes and 
then antigens are degraded by proteases (e.g. cathepsins) [3,9]. MHC class II molecules are assembled 
in the ER with the invariant chain (Ii) in the binding groove. MHC-Ii complexes are transported to 
endocytic vesicles (MIIC) where the Ii undergoes proteolysis, leaving in the cleft the MHC class II-
associated invariant chain peptide (CLIP). In the MIIC, antigenic fragments generated by resident 
proteases may bind MHC class II. CLIP has to be exchanged with peptides of higher affinity. CLIP 
removal is facilitated by HLA-DM. Peptide-MHC complexes are transported to the cell surface for 
presentation to CD4 T cells in the lymphoid system [3,9,10]. TCR recognition of pathogen-derived 
peptides bound to MHC, binding of the co-receptor CD4 and an additional co-stimulatory signal 
(B7:CD28 interaction), lead to the activation of naïve CD4 T cells, which then differentiate into distinct 
CD4 T helper effector subsets that produce diverse cytokines and differentially drive the immune 
response. The currently known types of T helper (Th) cells are: Th1 cells, Th17 cells, Th2 cells, T 
follicular helper cells (Tfh), and regulatory T cells (Treg) [7]. Th1 cells secrete IFNγ, which activates 
macrophages to respond against intracellular viral and bacterial infections. Th17 cells secrete IL-17 to 
activate and recruit neutrophils to fight extracellular bacterial and fungal infections. Th2 cells secrete 
IL-4 that acts on mast cells, basophils, and eosinophils to respond to parasite infections. Tfh cells 
activate naïve B cells to differentiate into antibody-producing cells. Treg suppress other effector CD4 
and CD8 T cells. Like CTL, most antigen-specific Th die after resolution of the infection, but a small 
percentage of the CD4 Th cells convert to memory cells [7]. 
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The antigen presentation pathways described above are simplified and exceptions have been 
reported [11]. There is evidence that demonstrates that MHC class I and II pathways are not always 
separated and that peptides derived from extracellular antigens can end up being presented by MHC 
class I molecules (i.e. cross-presentation) [12]. 
There are important structural differences between the MHC class I and II proteins (Fig. 1) that 
determine the specificity of peptide binding. Class I molecules consist of a transmembrane (α) chain 
and a β2-microglobulin chain linked non-covalently. The α chain has three structural domains (α1, α2 
and α3); the α1 and α2 domains form the peptide-binding groove that is closed at the ends, which limits 
the length of peptides able to bind [13]. Ninemer peptides (9-mers) are generally preferred for binding, 
but shorter and longer peptides have been reported [3]. Class II molecules consist of two 
transmembrane chains (α and β). The α1 and β1 domains form an open ended binding groove. Hence, 
longer peptides, generally 13-25 amino acids in length, bind MHC class II [13]. Similarly to class I, 
only nine amino acids fit into the groove; the remaining residues on both ends play a role in stabilizing 
the interaction [14,15].  
 
MHC genes 
Human MHC genes 
The genes that encode MHC class I and II proteins are highly polymorphic. In humans, the α chains of 
classical class I molecules are encoded by genes in the human leukocyte antigen (HLA)-A, HLA-B and 
HLA-C loci. Class II chains are encoded by genes in the HLA-DR, HLA-DQ and HLA-DP loci. HLA-
DRβ chain can be encoded by four loci (HLA-DRB1 and DRB3-5); however, only HLA-DRB1 is 
expressed in all individuals. The HLA-DRα chain, which exhibits limited polymorphism, is expressed 
from a single locus (HLA-DRA).  
Thousands of HLA-A, HLA-B and HLA-C alleles have been reported as well as more than a 
thousand HLA-DRB1 alleles [16]. Most of the differences between these alleles can be attributed to 
sequence polymorphisms in the binding groove that determine which peptides will be able to bind to a 
particular MHC allele. Therefore, different alleles generally have different binding preferences, 
although several groups of alleles may have similar preferences [17–19]. Despite their diversity, some 
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alleles are more frequently expressed. For example, HLA-A*0201 is expressed by 47% of the European 
population based on an allele frequency database [20]. 
Swine MHC genes 
Pigs also express MHC, called swine leukocyte antigen (SLA). Three loci encode the classical SLA 
class I (SLA-1, SLA-2, SLA-3) [21]. The expression level of the SLA-1 gene is the highest whereas 
SLA-3 is the lowest [22]. Several loci encode genes for expression of SLA class II proteins including α 
and β chain genes for SLA-DR and SLA-DQ. Pigs do not express DP proteins. As is true for human 
HLA-DRB1, SLA-DRB1 is commonly expressed, and like HLA-DRA, the SLA-DRA locus is highly 
conserved [21]. Current methods for the characterization of SLA alleles rely on DNA-based low- and 
high-resolution PCR sequence specific primers (PCR-SSP). This method uses allele-specific primers 
that cover polymorphic sites unique to a given allele [23]. While high-resolution PCR-SSP identifies 
specific SLA alleles, low-resolution SLA-typing differentiates alleles by groups that share similar 
sequence motifs [24,25]. SLA molecules are also highly polymorphic. As of October 2016, 116 SLA 
class I alleles (including SLA-1, SLA-2 and SLA-3 loci) and 82 SLA-DRB1 allele sequences have been 
deposited in the Immune Polymorphism Database (www.ebi.ac.uk/ipd/mhc/group/SLA).  
 
Experimental identification of swine T cell epitopes 
Several experimental approaches have been developed to evaluate HLA allele-specific binding 
preferences and map human T cell epitopes including intracellular cytokine staining, T cell 
proliferation, enzyme-linked immunosorbent spot (ELISpot), and HLA binding assays [26]. In vitro 
restimulation of T cells with overlapping peptides is the method most commonly used to identify swine 
immunogenic T cell peptides [27–36]. In this assay, peripheral blood mononuclear cells (PBMCs; 
consisting of T cells, B cells, dendritic cells, and natural killer cells) isolated from donor blood, exposed 
to a particular antigen by natural infection or vaccination, are stimulated with peptides. Peptides of 15-
20 residues, overlapping by at least 8 amino acids to cover all potential epitope 9-mer cores of an 
antigen, are used for stimulation. If the immune system has encountered a given epitope previously, a 
specific recall T cell response can be detected by the amount of released cytokines. IFNγ ELISpot assay 
is widely used in pigs to measure the frequency of antigen-specific cytokine-secreting cells [32–36]. 
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Although the ELISpot assay is a very sensitive method to measure epitope-specific immunogenic 
responses, its application to identification of T cell epitopes has some limitations. First, under certain 
conditions, T cell responses may be limited to a subset of dominant epitopes. For example, responses to 
subdominant epitopes may only be detected if the dominant epitopes are absent from the antigen during 
exposure or vaccination [37]. Second, T cells that recognize peptides bound to MHC might induce 
cytokines different from the one being tested [26,38]. Third, ELISpot assays do not provide information 
about the phenotype of cells producing IFNγ [26,38].  
SLA binding assays have also been applied to map swine class I T cell epitopes [39–42]. These 
assays quantify peptide-MHC affinity, which makes this approach appropriate for identification of 
peptide binders and non-binders. Competition assays using a labeled reference peptide bound to an 
MHC molecule and increasing concentrations of the query peptide are available for several HLA class I 
and II alleles, but they have been developed for only three SLA class I alleles [39–42].  
 
T cell epitope prediction tools 
There is a large and ever-increasing body of experimental data on MHC-peptide binding measurements 
that has been accumulated over the past few decades, which has enabled the development of highly 
accurate T cell epitope prediction algorithms for humans [43]. Epitope-prediction methods use these 
large sets of quantitative binding data to first train and then test HLA allele-specific models. Support 
vector machines (SVMs), hidden Markov models (HMMs) and artificial neural networks (ANNs) have 
been applied to develop predictions for characterized HLA alleles. For the purposes of predicting T cell 
epitopes for broad populations of subjects, HLA alleles are commonly clustered into “HLA supertypes”, 
based on their binding specificities, reducing the complexity generated by the polymorphism of HLA 
genes [17–19].  
For uncharacterized MHC molecules with limited or nonexistent experimental data, methods 
that infer binding preferences using information about multiple well-studied MHC alleles have been 
developed. A common assumption of these “pan-specific” methods is that MHC molecules with similar 
contact residues in their binding grooves have similar binding preferences [44].  
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The crystallographic structure of the HLA molecules revealed that the peptide-binding groove 
contains a number of pockets and that polymorphic residues in the HLA sequence are often involved in 
forming these pockets [13,45]. Consequently, the residues in the pocket define allele-specific binding 
preferences for particular amino acid side chains of the antigenic peptides [46]. Thus, for each MHC 
molecule, the profile of a given binding pocket can be defined by its residues and binding preferences 
[47]. Sturniolo et al. demonstrated that each “pocket profile” was nearly independent of the remaining 
HLA-DR binding groove [47]. The authors also showed that an MHC molecule could be defined in 
terms of its individual pocket profiles as a quantitative matrix of binding preferences. Therefore, once a 
pocket profile is determined experimentally, it can be shared with other HLA-DR molecules that have 
identical pocket residues [47].  
The pocket profile method has been applied to develop different pan-specific algorithms for T 
cell epitope prediction including TEPITOPE [47], TEPITOPEpan [48], PickPocket [49], and EpiMatrix 
[50]. Previous studies showed that the predictive performance of pan-specific methods for novel HLA 
alleles depends on the similarity of the pocket residues; the performance normally decreases as the 
similarity decreases [49]. For HLA alleles with limited quantitative data, algorithms based on the 
pocket profile method had better or comparable performance than methods that require a large amount 
of data for training (e.g. ANNs) [48,49]. 
 
Thesis motivation and outline 
The most frequent application of T cell epitope prediction tools is for identification of immunogenic 
peptides to design and develop vaccines against a wide variety of infectious pathogens [51–54]. They 
have also been applied for development of therapeutic vaccines [54–56], diagnostic tests [57], 
deimmunization of biological drugs [58,59], research related to transplantation [60], allergy [61], and 
autoimmunity [62]. Although epitope-based vaccines have yet to be licensed, several clinical trials 
involving epitope-based strategies are underway (clinicaltrials.gov) [63].  
Despite their multiple applications and ability to reduce time, effort and resources required to 
identify T cell epitopes [64], prediction algorithms are scarcely available for non-human species. This is 
mainly due to the limited experimental data available to develop predictors and may also be due to lack 
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of interest in epitope-driven vaccines for livestock animals. However, epitope-prediction tools for swine 
could have at least as many applications as for humans and would potentially accelerate porcine 
immunology research. One online tool is available for prediction of SLA class I epitopes [65]. This 
algorithm was trained and evaluated for prediction of three SLA class I alleles [40,65]. Prediction tools 
are not available for SLA class II alleles.  
To address the paucity of epitope prediction tools, Chapter 2 of this thesis describes the 
application of the pocket profile method to SLA alleles using binding preferences previously defined 
for HLA molecules to develop “PigMatrix”. This approach was developed to overcome the lack of 
quantitative data required to construct swine T cell epitope predictors. The pocket residues of SLA 
molecules were defined based on swine and human MHC crystal structures. Different scoring systems 
were tested to determine similarities between SLA and HLA pocket sequences and to identify the best 
human match for the purpose of inferring binding preferences of each SLA pocket in the binding 
groove. Using this information, matrices were built and their predictive performed tested retrospectively 
using datasets of SLA-restricted epitopes that were available for one SLA class II allele and three SLA 
class I alleles. For SLA class I alleles, the predictive power of PigMatrix was comparable to or higher 
than two other available methods. PigMatrix is the first tool available for prediction of SLA class II 
epitopes. These results demonstrated the potential of the pocket profile method and PigMatrix to 
develop predictions for SLA alleles without any training step involved, leveraging HLA binding 
preferences in order to circumvent training on published ligands as is generally required for quality 
predictive models. 
In Chapter 3, additional predictive matrices were developed for SLA class I and II alleles that 
have been reported to be prevalent in the U.S. swine population [24,25], and applied to identify 
potentially immunogenic peptides conserved in seven swine influenza A viruses. The immunogenicity 
(i.e. ability to induce an immune response) of 48 predicted T cell epitopes was determined by 
measuring IFNγ recall responses using PBMCs from pigs immunized with prototype DNA vaccines 
designed to deliver the peptides. Positive responses that were observed upon restimulation with pooled 
peptides as well as eleven individual peptides demonstrated that PigMatrix prediction identified SLA 
class I and II epitopes. However, it was shown after sacrifice of the animals that there was a mismatch 
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between the SLA alleles expressed by the animals in the study and the set of alleles utilized for the 
selection of the peptides. Therefore, cohort-specific SLA epitope predictors were developed and used to 
re-evaluate binding likelihood of the peptides. Retrospectively, cohort-specific PigMatrix analysis was 
able to predict non-immunogenic peptides efficiently. 
Influenza A virus (IAV) is an attractive model pathogen to evaluate swine T cell epitope 
predictions for several reasons. Importantly, IAV causes a highly contagious disease in pigs that has a 
significant impact to the swine industry mainly due to its high morbidity and reduction in the growth 
rate of infected pigs, complicating the management of commercial processing [66,67]. Furthermore, 
IAV is a zoonotic pathogen that can be transmitted between pigs and people, which is a matter of public 
health concern [68]. Swine-origin IAVs can adapt to the human host and spread between humans 
resulting in a pandemic, as was demonstrated during the 2009 influenza A (H1N1) pandemic [68,69]. 
Due the impact of IAV infections in pigs and humans, effective vaccines are highly desirable.  
Development of IAV vaccines is a significant challenge due to the variability of the virus. 
IAVs are enveloped viruses with negative-sense, single stranded, segmented RNA genomes. The eight 
RNA segments of IAV encode two nonstructural proteins (NS1 and NS2), the nucleoprotein (NP), three 
RNA polymerase proteins (PA, PB1, and PB2), two polypeptides synthesized from the PB1 mRNA 
(PB1-F2 and PB1-N40), the novel PA-X, two matrix proteins (M1 and M2), and two surface 
glycoproteins, hemagglutinin (HA), neuraminidase (NA); these two surface proteins determine different 
IAV subtypes [69]. Three different subtypes of IAV (H1N1, H1N2 and H3N2) co-circulate and are 
predominant in the North American swine population [70]. Reassortment of RNA segments from 
different viral strains infecting the same cell (antigenic shift) generates novel IAV strains [70]. Pigs are 
considered a “mixing vessel” that produces new IAV strains; they act as an intermediate host in cross-
species transmission of IAV because their respiratory epithelium expresses HA receptors that bind to 
both avian and human IAV strains [71]. In fact, most swine influenza viruses are reassortants composed 
of mixtures of human, avian and swine virus genes [70]. Accumulation of mutations in HA and NA 
(antigenic drift), also contributes to the diversity of swine IAV [70].  
Humoral immune response (antibodies) and CMI (comprised of responses from CTL and Th 
cells) participate in the adaptive immune response against IAV [72]. Neutralizing antibodies that target 
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HA block the attachment of this protein to sialic receptors in the host cells preventing infection [73]. 
Vaccine protection, mediated by anti-HA antibodies, against a different viral strain depends on the 
similarity between the HA proteins of the two viruses. Therefore, variability of HA can reduce the 
protective effects of pre-existing antibodies [73]. On the other hand, CMI can be broadly cross-reactive 
and protective against variety of IAV subtypes [74–78]. CMI does not prevent infection, but it does 
contribute to viral clearance of IAV as well as to reduced clinical signs and viral shedding in humans 
and mice [79,80]. Cell-mediated immune responses have also been observed in the lungs of pigs 
infected naturally [81], vaccinated with whole inactivated virus vaccine or live-attenuated vaccines [82–
85]. Reduction of morbidity is an important objective for swine IAV vaccines to prevent lack of 
appetite and loss of bodyweight.  
The genetic relationships and cross-reactive properties of antibodies to the HA proteins of the 
vaccine viruses are widely used to predict cross-protection. The hemagglutination inhibition (HI) assay 
measures the concentration of serum anti-HA antibodies against a given IAV strain and is commonly 
used for predicting protective immunity mediated by neutralizing antibodies to HA [86,87]. However, 
there are studies in pigs that show protection (reduced lung lesions, reduced viral titers in lungs and/or 
nasal swabs) conferred by swine vaccines even in the absence of cross-reactive antibodies [82,87–91]. 
In addition, the genetic lineage of the virus does not always predict antigenic phenotype. Therefore, 
new means of predicting the protective efficacy of swine IAV vaccines are needed. 
To determine the potential role of T cell epitope-driven CMI in protection, in Chapter 4, a 
method for comparison of predicted T cell epitope content (EpiCC) was developed. This method was 
applied to measure the relatedness, at the T cell epitope level, between the HA from swine IAV strains 
representing the major H1 clusters circulating in the North American swine population and those of H1 
viruses in a commercial vaccine. Using experimental data from previous efficacy studies testing one of 
the H1 viruses in the commercial vaccine against different challenge viruses [82,87–91], a certain level 
of T cell epitope relatedness associated with protection was identified. The results showed that the T 
cell epitope content relationship deduced from vaccine efficacy studies provides evidence that T cells 
contribute to vaccine efficacy. More vaccine efficacy data using diverse vaccine and challenge strains 
will be required to further validate and improve the predictive potential of this approach.  
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Fig. 1. Comparison of MHC class I and class II crystal structures. (Top; side view) Ribbon 
diagrams of class I (HLA-A*0201; PDB id: 3MRE) and class II (HLA-DRB1*0201; PDB id: 1T5W) 
MHC proteins. Grey regions are α-domains, orange regions β-domains. The transmembrane and short 
cytoplasmic domains, which are not visualized in the crystal structures, extend towards the bottom of 
the figure. Peptides (green) bind above the large β-sheet and between the α-helical regions. The domain 
organization of class I (α1, α2, α3, β2m) and class II (α1, α2, β1, β2) is different; however, their three 
dimensional structures are very similar. (Bottom; top view) Surface representations of MHC molecules 
are shown and peptides are represented as spheres. Small conformational alterations and amino acid 
substitutions in the peptide-binding site account for the difference in peptide length preference between 
class I (8–10mers) and class II (>12mers). The class I peptide has its ends buried in the binding site, and 
arches away from the HLA protein in the center. The class II peptide is straight, and extends out of the 
open ends of the groove. 	 	
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Abstract 
Background: T cell epitope prediction tools and associated vaccine design algorithms have accelerated 
the development of vaccines for humans. Predictive tools for swine and other food animals are not as 
well developed, primarily because the data required to develop the tools are lacking. Here, we 
overcome a lack of T cell epitope data to construct swine epitope predictors by systematically 
leveraging available human information. Applying the “pocket profile method”, we use sequence and 
structural similarities in the binding pockets of human and swine major histocompatibility complex 
proteins to infer Swine Leukocyte Antigen (SLA) peptide binding preferences.  
Methods: We developed epitope-prediction matrices (PigMatrices), for three SLA class I alleles (SLA-
1*0401, 2*0401 and 3*0401) and one class II allele (SLA-DRB1*0201), based on the binding 
preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket. The 
contact residues involved in the binding pockets were defined for class I based on crystal structures of 
either SLA (SLA-specific contacts, Ssc) or HLA supertype alleles (HLA contacts, Hc); for class II, only 
Hc was possible. Different substitution matrices were evaluated (PAM and BLOSUM) for scoring 
pocket similarity and identifying the best human match. The accuracy of the PigMatrices was compared 
to available online swine epitope prediction tools such as PickPocket and NetMHCpan. 
Results: PigMatrices that used Ssc to define the pocket sequences and PAM30 to score pocket 
similarity demonstrated the best predictive performance and were able to accurately separate binders 
from random peptides. For SLA-1*0401 and 2*0401, PigMatrix achieved area under the receiver 
operating characteristic curves (AUC) of 0.78 and 0.73, respectively, which were equivalent or better 
than PickPocket (0.76 and 0.54) and NetMHCpan version 2.4 (0.41 and 0.51) and version 2.8 (0.72 and 
0.71). In addition, we developed the first predictive SLA class II matrix, obtaining an AUC of 0.73 for 
existing SLA-DRB1*0201 epitopes. Notably, PigMatrix achieved this level of predictive power without 
training on SLA binding data. 
Conclusion: Overall, the pocket profile method combined with binding preferences from HLA binding 
data shows significant promise for developing T cell epitope prediction tools for pigs. When combined 
with existing vaccine design algorithms, PigMatrix will be useful for developing genome-derived 
vaccines for a range of pig pathogens for which no effective vaccines currently exist (e.g. porcine 
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reproductive and respiratory syndrome, influenza and porcine epidemic diarrhea). 
 
Keywords: PigMatrix, EpiMatrix, Computational vaccinology, Epitope prediction, HLA, SLA, MHC, 
class I, class II, Porcine, PRRSV, Influenza, Genome-derived vaccine, T cell epitope  
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Background 
The interaction of Major Histocompatibility Complex (MHC) proteins with peptides derived from 
protein antigens plays a key role in the adaptive immune response mediated by T cells. The 
MHC:peptide complex presented on the surface of a cell is recognized by the T cell receptor (TCR), 
which activates the T cell and drives the immune response. There are two classes of MHC molecules: 
MHC class I presents peptides of intracellular origin to CD8+ T cells (cytotoxic T cells, or CTL) and 
MHC class II presents peptides of extracellular origin to CD4+ T cells (T-helper cells, or Th). Both 
classes of molecules have similar tertiary structure. Class I molecules have a transmembrane (α) chain 
noncovalently associated with β2-microglobulin where the α1 and α2 domains form the peptide-binding 
groove; class II molecules have two transmembrane chains (α and β) where the α1 and β1 domains form 
the peptide-binding groove. The MHC class I binding groove is closed, which restricts the length of 
bound peptides to 8-10 residues; the MHC class II binding groove on the other hand, is open, and 
peptides can extend beyond the ends of the groove, allowing binding of longer and more flexible 
peptides of variable lengths (typically 13-25 amino acids) [1]. 
The tertiary structure of MHC molecules is relatively conserved, even across species. For 
example, crystallographic studies have shown similarity between Human Leukocyte Antigen (HLA; 
human MHC) and Swine Leukocyte Antigen (SLA; swine MHC) molecules [2]. The SLA-1*0401 class 
I allele has been crystallized in complex with peptides derived from 2009-pandemic H1N1 (pH1N1) 
swine-origin influenza A virus and Ebola virus. A structural comparison revealed that the SLA class I 
molecule, SLA-1*0401 contains six pockets in its binding groove, similar to HLA class I molecules. 
The root-mean-squared deviation (RMSD) for all of the Cα atoms in SLA-1*0401 and HLA-A*1101, 
which has the highest identity with SLA-1*0401 (78%), was <0.7Å indicating a similar arrangement of 
their backbones. Furthermore, three out of 23 influenza SLA-1*0401 binders were identical to 
previously defined peptides presented by HLA-A*0101 [2]. For SLA class II, no crystal structures are 
available, but amino acid SLA-DR sequences are highly similar to their human counterparts. For 
example, the amino acid sequences of SLA-DRB1*0201 and HLA-DRB1*0101 are 79% identical.  
Due to the importance of peptide binding to MHC molecules in the immune response, human T 
cell epitope prediction tools have been developed based on a range of approaches and are widely used 
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in vaccine development and experimental immunology [3]. The availability of a large and expanding 
database of validated MHC ligands has contributed to the development of more accurate algorithms. 
Epitope predictions using these tools reduce the time and effort required to identify T cell epitopes [4]. 
The number of epitope prediction tools is more limited for pigs due to the paucity of experimental data 
available. To overcome the lack of quantitative measurements of MHC interaction for a large number of 
HLA alleles, ‘pan-specific’ methods have been implemented for prediction of T cell epitopes that bind 
to MHC for which experimental data are limited or not available. Pan-specific methods use 
experimental binding data and amino acid sequences of multiple MHC alleles to infer binding 
preferences to uncharacterized MHC molecules. These methods have been used for development of 
prediction tools for MHC class I [5–7] and II alleles [8–11], but only NetMHCpan has been used for 
prediction of SLA class I-restricted peptides [12–16]. This method is based on artificial neural networks 
(ANN) trained using as input a pseudo-sequence composed of the polymorphic residues in the binding 
groove of a given MHC, a peptide sequence and the experimental affinity data. To our knowledge, there 
are no in silico tools that are available for SLA class II.  
Sturniolo et al. first described a method for using existing data to develop new epitope 
predictors, the pocket profile method, in 1999 [17]. It has been used to develop pan-specific methods 
for predicting binding of peptides to HLA class I and II alleles [9, 18]. The approach depends on the 
identification of certain polymorphic regions within HLA molecules that are known to be the areas of 
contact between peptides and the binding groove of HLA [19–21]. Contact residues from the HLA 
molecule that bind the R group (side chain) of a specific amino acid within a linear peptide can be 
considered to form a pocket for that R group. Thus, each ‘pocket’ can also be described in terms of its 
amino acid binding preferences (‘pocket profile’). The pocket profiles are nearly independent of the 
remaining binding groove. So, this method assumes that two MHC alleles with identical pocket residues 
will have the same pocket profile. Therefore, given sufficient information about the contact residues of 
the set of pockets in the binding groove of an MHC and experimentally determined pocket profiles, it is 
possible to compose predictive matrices in silico. The method was originally applied to develop 
TEPITOPE, an algorithm for prediction of peptide ligands to 51 HLA class II alleles with known pocket 
residues [17] and then extended to any HLA-DR molecules with similar pockets (TEPITOPEpan) [9]. A 
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similar method has also been used in the PickPocket algorithm for MHC class I prediction [18]. 
Whereas TEPITOPEpan uses pocket profiles from TEPITOPE, PickPocket generates binding 
preferences using position-specific scoring matrices (PSSMs) from binding data directly. Although no 
publications exist using these algorithms for SLA binding predictions, SLA alleles are available for use 
in the PickPocket server (www.cbs.dtu.dk/services/PickPocket/).  
EpiMatrix is a matrix-based algorithm that uses the pocket profile method to predict potential 
HLA class I and II T cell epitopes. The first version of this algorithm was developed in 1996, and newer 
versions have been extensively validated in vitro in HLA binding assay and human T cell assays and in 
animal studies using HLA transgenic mouse models [22–26]. For common class II alleles, EpiMatrix 
appears to predict more accurately than many available epitope-mapping algorithms [27]. Comparative 
performance for EpiMatrix class I predictions has not been published; however, the tools have been 
successfully applied to identify class I-restricted T cell epitopes in human pathogens [28–30]. The 
pocket profile method was used to develop a matrix for a bovine MHC class I allele [31] and in the 
early 2000s, this method was also used to derive SLA class II prediction matrices from EpiMatrix, but 
this work was not published.  
This paper describes the development and retrospective validation of predictive matrices to 
map T cell epitopes for SLA class I (SLA-1*0401, 2*0401, 3*0401) alleles and a class II (SLA-
DRB1*0201) allele. “PigMatrix” matrices are built based on the pocket profile method using EpiMatrix 
pocket profiles for HLA epitope prediction. While these alleles represent a small subset of commonly 
expressed alleles in pigs [32–36], they were selected for their available quantitative peptide data [13–
16, 37–39]. As before, we assumed that predictive matrices developed for HLA alleles should function 
as reasonable proxies for the prediction of ligands to SLA molecules with similar pocket profiles. Thus, 
we developed ‘composite matrices’ by selecting the most similar HLA pocket (best human match) for 
each SLA pocket, and built matrices composed of the corresponding HLA binding preferences (Fig. 1).  
Two methods were used to define the pocket contact residues considering different scenarios 
of availability of SLA crystal structures. In the first scenario, SLA crystal structures were available, so 
pockets were defined from these structures. In the second, no SLA crystal structures were available; 
therefore, contact residues were selected based on crystal structures of HLA. We also tested different 
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substitution matrices (PAM and BLOSUM) to score pocket similarity to define the best human match. 
PigMatrix was benchmarked against existing SLA prediction tools for class I alleles. Benchmarking 
against other SLA class II predictors was not possible as no other prediction algorithms are available. 
The results demonstrate the potential of this approach to develop matrices to make accurate predictions 
for both SLA class I and II alleles for which experimental binding data are limited or even non-existent.  
 
Methods 
Datasets  
Unique 9-mer peptides with reported binding measurement to a specific SLA allele were compiled from 
the literature into two datasets: one comprising binders and the other, non-binders, for each of three 
class I (SLA-1*0401, 2*0401, 3*0401) alleles [2, 13–16]. The SLA-1*0401 dataset included 133 
binders and 46 non-binders; 2*0401 included 24 binders and 46 non-binders; and 3*0401, 27 binders 
and 46 non-binders. Twenty-five (14%) of the SLA-1*0401 peptides were reported by Zhang et al. [2]; 
the remaining peptides for 1*0401, 2*0401 and 3*0401 were published by Pedersen et al. in different 
publications [13–16]. For class II, a dataset was created with peptides specific to SLA-DRB1*0201 
from the literature [37–39]. This dataset has 33 binders and 171 non-binders. Peptides with 
contradictory (both positive and negative) results were discarded (Supplemental Table 1). Additionally, 
we generated a set of 100,000 unique 9-mer peptides from random sequence proteins with the average 
amino acid frequencies of the proteins in the Swiss-Prot database for use as a control data set, as 
previously described [31]. The random proteins were generated using the RandSeq tool from ExPASy 
[40].  
MHC sequences 
Complete amino acid sequences from SLA proteins, along with HLA class I (HLA-A*0101, A*0201, 
A*0301, A*1101, A*2402, A*6801, B*0702, B*0801, B*2705, B*3501, B*4403, B*5101) and class II 
alleles (HLA-DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, 1501), were obtained from the IPD-
MHC Database (www.ebi.ac.uk/ipd/). It is important to clarify that the HLA alleles for which binding 
preferences are available in EpiMatrix are families of alleles that share pocket preferences, rather than 
individual alleles. The alleles represent 12 class I supertypes [41] and eight class II supertypes [42]. 
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Binding pocket residues 
Six pockets (A-F) and five pockets (A-E) were considered for class I and II, respectively. Pockets for 
peptide positions 4, 5 and 8 for class I and 2, 3, 5, and 8 for class II were not considered due to their 
minimal effect on binding [17, 19, 43]. For each pocket, contact residues (pocket sequences) were 
defined as either (1) SLA-specific contacts (Ssc) derived from SLA crystal structures or (2) HLA-based 
contacts (Hc) derived from HLA crystal structures (Fig. 2A). The Ssc approach was applied only to 
SLA class I alleles using crystallographic data available for SLA-1*0401 (PDB:3QQ3 and 3QQ4) [2]. 
For Hc, representative crystal structures from HLA class I and II supertype alleles [41, 42] with bound 
9-mer (for class I) or longer peptides (for class II) and the highest resolution were analyzed to define the 
contact residues (Supplemental Table 2). Four class II supertype alleles (HLA-DRB1*0101, 0301, 
0401, and 1501) had crystal structures available. 
We considered binding pocket contact residues to be amino acids with atoms within 5.0Å of 
those in the bound peptide. Residues were selected using PyMOL (Schrodinger, LLC). Only amino 
acids with the side chain oriented towards the peptide were included. Thus, each pocket included the 
union of contact residues in all the MHC crystal structures of a given class. For class II alleles, since the 
alpha subunit of HLA-DR (HLA-DRA) is practically invariable [44], only residues in the beta subunit 
were included. The amino acids in the positions defined as contact residues according to Ssc and Hc 
were extracted from HLA sequences and compiled into a pocket library (Fig. 2B), where each pocket is 
a non-contiguous sequence of residues ordered by their positions.  
Composite matrix construction 
Each SLA protein sequence was aligned to a reference HLA sequence (HLA-A*0101 for class I and 
HLA-DRB1*0101 for class II) to extract its contact residues (Fig. 2C) based on Ssc and Hc approaches. 
SLA pockets were compared to the HLA pocket library to identify the best human match for each SLA 
pocket. SLA-HLA pocket similarity was determined using PAM and BLOSUM substitution matrices 
for closely (PAM30 and BLOSUM90) and distantly related (PAM120 and BLOSUM62) protein 
sequences [45, 46]. For a pocket comparison between SLA sequence x and corresponding HLA 
sequence y, both of length N, the similarity score was calculated as the sum of the similarity scores of 
each amino acid i using a specific substitution matrix M. The score was then divided by the similarity 
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score of the SLA pocket compared to itself. 
sim!(!, !) = M[!! , !!]!!!!M[!! , !!]!!!!  
The HLA pocket with the highest similarity score was considered to be the best human match 
(Fig. 2D). The pocket profiles of the best human matches for each pocket were then combined to form 
composite matrices (Fig. 2E). 
Matrix validation and performance evaluation 
Composite matrices were used to score a set of random 9-mer peptides. The raw binding score 
bindraw(p) for each peptide p was calculated as the sum, over a set i of relevant peptide positions, of the 
coefficient K[i,pi] of the amino acid pi at position i in p. Positions 1, 2, 3, 6, 7, and 9 were used for class 
I and 1, 4, 6, 7, and 9 for class II, as those positions most interact with each SLA pocket. 
bindraw p = ![!, !!]! ∈!  
The average µ and standard deviation σ of the scores were used to normalize scores into a Z-
score scale (binding likelihood score). 
! = bind!"# p − !!  
Next, the ability of the composite matrices to separate binders from non-binders and binders 
from a set of random peptides was evaluated by comparing the mean of the Z-scores of the datasets 
[28]. Differences were evaluated for significance by Wilcoxon-Mann–Whitney test. For class II binders 
longer than 10 amino acids, 9-mers overlapping by eight amino acids were scored because in general, 
the lengths of MHC binding cores are 9 amino acids [47]. The 9-mer frame with the highest Z-score 
was selected to be the most likely MHC binder and its score was used for calculation of the mean Z-
score of binders and non-binders. In addition, for each allele, the HLA matrix with the lowest overall 
pocket identity with the SLA was used to score both set of peptides, binders and random peptides, as a 
negative control matrix. 
Peptides in the top 5% of the normal curve, where the Z-score is greater than or equal to 1.64, 
were considered to be potential binders. This threshold has been shown to identify peptides that are 
highly likely to bind HLA molecules [22]. So as to evaluate the predictive performance of the matrices, 
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we calculated the area under the receiver operating characteristic (ROC) curve (AUC) using the 
sensitivity and 1 – specificity values for the same dataset of binders and non-binders. 
Finally, PigMatrix SLA class I predictions were compared to those of PickPocket 1.1 and 
NetMHCpan 2.4 and 2.8. A threshold of 500 nM in binding affinity (or 0.426 prediction score based on   
1 – log50K(affinity)), was set to classify binders and non-binders as previously described [6, 18].  
 
Results 
Pocket residues 
The contact residues that form the binding pockets in SLA were defined from (1) SLA-1*0401 crystal 
structures (SLA-specific contacts, Ssc), and (2) HLA class I and II crystal structures (HLA contacts, 
Hc). Fig. 3 shows contact residue similarities and differences for SLA-1*0401 in determinations using 
Hc and Ssc. Thirty-nine positions were identified with Hc, of which 34 were in common with Ssc 
(shown in light blue in Fig. 3) and five were unique to Hc (in orange); there were no positions unique to 
Ssc. Several amino acids were involved in more than one pocket; however, this was more frequent for 
Hc than Scc due to the nature of the approach; only 23 of the 34 common positions belonged to exactly 
the same pockets by both definitions (positions shown in bold and underlined in Fig. 3). Hc included for 
each pocket, the union of amino acids over all the HLA crystal structures analyzed. Based on Hc, 
positions 97, 99 and 114 were part of four pockets; these residues are located in the central part of the 
MHC binding groove and depending on the characteristics of their R chain and the bound peptide, they 
can interact with more than one residue of the ligand. We also observed that the total number of contact 
residues per pocket was lower in Ssc. The main differences in SLA class I were observed for pockets C 
and D where SLA structures had fewer contact residues involved in the binding. Pocket F, on the other 
hand, was identical for both. 
For class II, only Hc was applied because no SLA-DR crystal structures were available. 
Twenty-two positions were considered in contact with ligands; four positions were common to three 
pockets, four to two pockets and 14 were involved in only one pocket. Five positions were included for 
pocket A, seven in B, seven in C, eight in D, and seven in F (Supplemental Table 3). In pockets B, C, 
D, and E, we identified in total eight allele-specific pocket residues; Y30 in pocket B for HLA-
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DRB1*1501, D28 and R74 in pocket C for DRB1*0301, Q70 and R74 for DRB1*0301 and R13 for 
DRB1*1501 in pocket D, and V38 for DRB1*0301 and Y37 for DRB1*0401 in pocket E. 
Matrix construction, validation and evaluation 
We built composite matrices for each SLA allele and evaluated whether they were able to distinguish 
SLA allele-specific binders from non-binders and random peptides (Fig. 4). In some cases, the best 
human matches were the same regardless of the approach used to define pocket residues and the pocket 
similarity scoring method applied; therefore, prediction results were identical (e.g. Fig. 4 top, SLA-
2*0401). For SLA-1*0401 and 2*0401, two and four scoring methods respectively, generated Ssc 
matrices capable of separating binders from non-binders (highlighted in gray in Fig. 4 top). For these 
matrices, mean Z-scores of binders were above the threshold to be considered a potential binder (1.64) 
and non-binder Z-scores were below. Furthermore, the difference between the sets of peptides was 
statistically significant (p<0.001) using a Wilcoxon-Mann-Whitney test. None of the class I Hc matrices 
was able to distinguish with statistical significance binders from non-binders. Likewise, for all SLA-
3*0401 matrices, mean Z-scores of the binders were either not above the 1.64 threshold or the non-
binders had higher mean Z-scores. For class II allele SLA-DRB1*0201, binders scored using Hc 
matrices were above the threshold and were statistically distinct from mean Z-scores of the non-binders 
(p<0.01). Negative control matrices for all SLA alleles (using HLA alleles with the lowest overall 
pocket identity) did not separate binders from random peptides (means range from −0.57 to 1.13), 
showing that the selection of the best human match based on similarity is critical. In sum, these results 
show that some composite class I Ssc matrices and class II Hc were able to separate binders from 
random peptides and non-binders. 
To evaluate the predictive performance of the matrices, we built ROC curves and then 
calculated the AUC. For the AUC, a value of 0.5 corresponds to a random prediction and a value of 1 to 
a perfect prediction. Fig. 5 shows a comparison of the AUCs of Ssc and Hc matrices, PickPocket and 
NetMHCpan. For class I, matrices based on Ssc had higher AUCs than Hc-based matrices. Class I and 
II matrices constructed using PAM30 to score pocket similarity had higher AUCs compared to matrices 
constructed using PAM120, BLOSUM62 and PAM120, with one exception (Hc SLA-1*0401 built 
using BLOSUM62). Compared to PickPocket and NetMHCpan 2.4 and 2.8, PigMatrix’s AUC was 
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equivalent or better for SLA-1*0401 and 2*0401; however, due to the nature of the tests, we could not 
assess statistical significance. It is worth noting that, in contrast with NetMHCpan 2.8, SLA peptide 
data did not contribute to training PigMatrix. 
The SLA-3*0401 PAM30-Ssc matrix had the lowest AUC (0.59). This was not unexpected as 
matrices for this allele were unable to separate binders from non-binders as described above (Fig. 4). 
For these reasons, we examined the binding preferences of the best human matches for the PAM30-Ssc 
matrix and compared them to the amino acid frequencies in the sets of binders and non-binders. The 
most evident differences were observed in pocket B. The best human match for pocket B was HLA-
A*0301 (simPAM30 0.49). Of all binders reported for SLA-3*0401, the most common residue in position 
two (Pocket B) was arginine, found in 37% of binders, followed by alanine, found in 19% of binders. 
These frequencies were more similar to the binding preferences in HLA-B*2705 (simPAM30 0.17) pocket 
profile, in contrast to A*0301, which had negative coefficients for arginine and alanine. Based on this 
observation, we modified pocket B of PAM30-Ssc matrix from A*0301 to B*2705 (SscModB). This 
matrix had a higher AUC (0.81) than the original matrix (Fig. 5). This result showed that predictions 
could potentially be improved by selecting best human matches based on similarity in terms of binding 
preferences if binding information is available. However, it is important to note that this improvement 
in the AUC was specific to the set of peptides available to date, and further prospective studies are 
needed to validate the preference of this particular pocket. 
Overall, these results demonstrate that matrices built using contact residues from SLA 
structures and using the PAM30 substitution matrix to identify the best human match for each pocket, 
had the best predictive power of the approaches that were tested. Although the matrices showed 
predictive power, the limited number of known binders makes the AUC values less robust. For this 
reason, an analysis of a larger dataset of SLA-specific binders and non-binder peptides will be required 
to revalidate the predictive power of the matrices. 
 
Discussion and conclusions 
Immunoinformatics tools have accelerated the identification of epitopes and design of human vaccines. 
However, comparable tools have not been applied extensively to pigs. During the last two decades, 
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swine T cell epitope discovery has been based on experimental studies of numerous overlapping 
peptides [37–39, 48–54]. While these studies are essential for validating T cell epitope prediction tools, 
they can be expensive and time consuming. To reduce experimental effort and expedite the process, 
algorithms developed for human T cell epitope prediction have also been used to identify porcine 
epitopes [55–57]. However, the substitution of HLA predictions for SLA predictions may not reflect the 
fine specificity of SLA binding, which limits the efficacy of this oversimplified approach. To overcome 
this, we have developed PigMatrix, a simple yet effective method that leverages available data (SLA-
binding peptides, SLA structures and HLA binding data) and pocket profiles already constructed for 
HLA-based epitope prediction in EpiMatrix to predict potential T cell epitopes for SLA class I and II 
alleles. Using the pocket profile method and the concept that pockets that have similar amino acids will 
share similar binding preferences, we built and validated matrices that were able to separate SLA-
restricted peptides from random peptides and non-binders. 
Human pan-specific tools based on the pocket profile method have been described for 
prediction of class I (PickPocket) and class II T cell epitopes (TEPITOPEpan) [9, 18]. These methods 
defined the amino acids in the pockets from HLA crystal structures. Similarly, we defined SLA-specific 
contacts (Ssc) from two crystal structures available for SLA-1*0401. Additionally, we extrapolated the 
pocket residues from crystal structures of HLA class I and II crystal structures (Hc). Both approaches 
assume for a given pocket that all contact residues are conserved across all class-specific MHC 
molecules. However, because there are differences in the pocket residues between MHC alleles and 
even between the same allele structures depending on the ligand [2], this simplification is a limitation of 
the peptide:MHC modeling approach. Even so, it is a reasonable approximation when structural 
information is limited. For class I, differences in the pocket residues using the Hc and the Ssc 
approaches were noticeable and impacted the subsequent selection of the best human match to build the 
prediction matrices. Matrices based on pockets defined from SLA structure-specific contacts performed 
better than HLA-derived pockets. While a definition of the contact residues based on several HLA 
structures account for the intra- and inter-allelic variability of binding pockets, it also dilutes the 
importance of key residues in the peptide:MHC interaction. We speculate that more allele-specific 
pockets could potentially improve the selection of the best human match and therefore the predictions. 
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Selection might be also improved by weighting the similarity score by conservation of key contact 
residues. 
PickPocket and TEPITOPEpan use a method based on BLOSUM62 to calculate a weighted 
score of specificity to define the most similar HLA-derived pocket. For PigMatrix, in addition to 
BLOSUM62, we used PAM120, which is considered equivalent to BLOSUM62 for comparison of 
distantly related proteins [46], to calculate pocket similarity. We also included PAM30 and 
BLOSUM90, which are both designed to score similarity between closely related protein sequences. 
The SLA matrices with the highest AUC were based on PAM30 using both Hc and Ssc, with only one 
exception. If we consider the pocket contact residues as short pseudo-sequences, the better performance 
of PAM30-based matrices might be explained because low-numbered PAM matrices are more efficient 
for searches involving short sequences. BLOSUM62 on the other hand, performs better to identify 
distant homologs using longer sequences. BLOSUM90, like PAM30, is used for closely related 
sequences; however, it is not recommended for short peptides [46] and unsurprisingly did not perform 
as well as PAM30 in these studies. 
Predictive methods for porcine T-cell epitopes are limited, and none existed previously for 
SLA class II. PigMatrix is the first tool to make binding predictions for an SLA-DR allele. Class II 
predictions were limited to the Hc method because no SLA-DR molecule has been crystallized. Since 
SLA-DR-specific binding data are scarce, predictions require further prospective validation. While it is 
not possible at this time to benchmark the SLA-DR matrix against other predictors, a comparison can be 
made for the SLA class I matrices developed here. NetMHCpan has been used for SLA binding 
predictions. PickPocket, which is also based on the pocket profile method, has been described primarily 
for HLA class I [18], but predictions are also available for SLA alleles. In this study, for an existing set 
of published peptides, PigMatrix performed equally or better than two versions of NetMHCpan and 
PickPocket for SLA-1*0401 and 2*0401. While PigMatrix and PickPocket derive SLA binding 
preferences from HLA binding data, NetMHCpan artificial neural networks are trained using 
information derived from available binding data as well as peptide sequences and MHC sequence 
information [6]. It was previously demonstrated that in a scenario where the quantitative binding data 
were limited for human and non-human MHC alleles, PickPocket performed better than NetMHCpan 
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[18]. This is also evident when NetMHCpan 2.4 results are compared to NetMHCpan 2.8 predictions. 
NetMHCpan 2.4 was trained with a limited set of SLA binders and its predictions were equivalent to 
random selection (average AUC 0.47). Version 2.8, on the other hand, was trained with more data and 
its performance improved for the alleles we evaluated (average AUC 0.76). Conversely, PigMatrix was 
not trained with SLA-specific binding data and performed similarly or better than NetMHCpan 2.8 
predictions for two of three class I alleles we tested. Moreover, because the number of published 
peptides is limited, we were not able to compile a test dataset of peptides known to be different from the 
training set used by NetMHCpan 2.8. Hence, it is possible that NetMHCpan 2.8 performance was 
overestimated. 
For SLA-3*0401, PickPocket and NetMHCpan 2.8 outperformed PigMatrix. Upon closer 
analysis, these results provided an example of how PigMatrix could be improved. We were able to build 
a better performing model by modifying pocket B in the matrix constructed using PAM30-Ssc. This 
might be explained by the role of the amino acid in position two of the peptide as a binding anchor and 
its specific interaction with this pocket. It is also worth noting that the HLA pocket library we used was 
limited to 12 class I and eight class II supertypes alleles available in EpiMatrix. It is possible that pocket 
sequences from other HLA alleles and their profiles are more similar to SLA pockets. Therefore, if the 
number of HLA alleles in the library is increased, we might find better human matches for SLA 
pockets, which could potentially improve matrix performance. 
So as to illustrate the PigMatrix approach, we built initially matrices for only three SLA class I 
alleles and one SLA class II allele for which quantitative peptide data were available. These alleles are 
commonly expressed in different porcine breeds and cell lines for in vitro culture [32–36]. However, 
like HLA, SLA diversity is considerable. These results demonstrate the potential of the approach to be 
extended to SLA alleles with limited or nonexistent epitope binding data. Thus, future versions of 
PigMatrix will include a more comprehensive and representative set of matrices for SLA alleles 
expressed in outbred porcine populations. Moreover, prospective in vitro and in vivo evaluation of 
PigMatrix predictions will help to refine the matrices. 
We developed the PigMatrix tool with the intent to integrate it into the iVAX toolkit, which is 
a comprehensive set of tools for computational vaccine design that includes EpiMatrix, Conservatrix, 
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ClustiMer, EpiAssembler, JanusMatrix, and VaccineCAD [58]. When the PigMatrices are used to 
substitute for HLA matrices (EpiMatrix) in iVAX, all of the existing suite of iVAX vaccine design tools 
can be used with the SLA epitope predictions, which makes it possible to envision accelerated 
development of novel T cell epitope-based vaccines or whole subunit vaccines optimized for epitope 
content that protect against infectious disease in swine.  
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Fig. 1. Illustration of PigMatrix development using the pocket profile method. Three pockets (A, B, 
and C) from human (HLA) and swine (SLA) MHC molecules are represented as different shapes and 
colors. The contours of the pockets are shown in bold black lines. HLA pockets from two HLA alleles 
(HLA-A*0101 and B*4403) are shown in the first two rows. For each pocket in a target SLA, in the 
third row, we identified the most similar HLA pocket (best human match) and combined their pocket 
profiles (binding preferences expressed as coefficients) to build composite predictive matrices 
(PigMatrix). 
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HLA-A*0101 HLA-B*4403 HLA-A*0101 
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HLA-A*0101 
Pocket A Pocket B Pocket C 
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Fig. 2. PigMatrix algorithm. (A) Residues in contact with the peptide are determined with respect to a 
crystal structure of either an SLA allele (Ssc) or an HLA supertype allele (Hc). Class I supertype alleles 
are represented by three HLA molecules. (B) Contact residues defined by either Ssc or Hc are extracted 
from HLA sequences and compiled into a library of HLA pockets (HLA pocket library). Pocket A 
positions and the extracted pocket sequences for Ssc and Hc are marked with *. (C) For a target SLA 
allele, contact residues (defined by Ssc or Hc) are identified by aligning the SLA sequence to a 
reference HLA sequence. (D) SLA pocket sequences are compared to those in the HLA pocket library 
to identify the best human match. (E) Binding coefficients of the best human match for each SLA 
pocket sequence are compiled to build a PigMatrix. Coefficients are represented in red to blue scale 
(high to low binding likelihood). 
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Fig. 3. Comparison of contact residues in the binding pockets based on SLA-specific contacts 
(Ssc) and HLA contacts (Hc). Top: Schematic representation of the crystal structure of SLA-1*0401 
(PDB:3QQ4; residues 1 to 181 rendered with PyMOL (Schrodinger, LLC)) showing the residues 
involved in the binding pockets. SLA contact residues and the ligand (ATAAATEAY, yellow) are 
represented as sticks. Residues common for both Hc and Ssc approaches are show in light blue; residues 
unique to Hc in orange. Bottom: Positions in the SLA binding pockets are shown. The first column 
(SLA position) is the residue and position number in the SLA-1*0401 protein sequence 
(Genbank:2352988). Residue positions shown in bold and underlined are identical (i.e. amino acid 
involved in the same pocket(s)) for both approaches. Positions in light blue are common for both 
approaches; positions in orange are unique to Hc. The next columns show, shaded in gray, the positions 
involved in pockets A through F that interact with relative ligand positions (peptide position). The last 
column (Count) is the number of pockets in which an amino acid participates. The last row (Total) is 
the total number of residues in each pocket. 
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Fig. 4. Validation of composite matrices. Top: Binding likelihood (Z-score) means and standard 
deviations (sd) of binders and non-binders calculated using the matrices built based on Ssc and Hc and 
different scoring methods for pocket selection are shown for SLA class I and II alleles. Z-score means 
and sd calculated using negative matrices, HLA matrices with the lowest overall pocket identity for 
each SLA allele, are also shown. Instances where the Z-scores of binders and non-binders were 
statistically different (p-value ≤ 0.05) using a Wilcoxon-Mann–Whitney test, are shown in bold; those 
with Z-score means above or below 1.64 for binders or non-binders, respectively, are shown in gray. 
Bottom: Comparison of binding likelihood (expressed as Z-score) between matrices (PAM30-Ssc and 
Negative) shown as density estimates (smoothed histograms). Note that y-axes are differently scaled. 
Binders and non-binders were scored with PAM30-Ssc (for class I), PAM30-Hc (for class II) and 
Negative control matrices. 100,000 natural random 9-mers were scored with either PAM30-Ssc (class I) 
or PAM30-Hc (class II). The black line indicates the threshold at which a 9-mer is considered a 
potential binder (Z-score of 1.64). Ssc was not applied to SLA-DRB1*0201 because crystal structures 
are not available. 
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Fig. 5. Matrix performance comparison. AUCs of the matrices built for SLA class I and II alleles are 
shown. The highest AUC for each method is shown above the bars. For SLA-3*0401, AUC of SscModB, 
a PAM30-Ssc matrix with a pocket B profile different than the best human match, is shown in a dashed 
rectangle to illustrate the impact of pocket B. If one or more matrices for the same approach (Ssc or Hc) 
have equal AUC, it is indicated with *.  
  
 44 
CHAPTER 3 
Manuscript published in PLOS ONE, July 2016 
In vivo validation of predicted and conserved T cell epitopes in a swine influenza model 
  
Andres H. Gutiérrez1, Crystal Loving2, Leonard Moise1,3, Frances E. Terry3, Susan L. Brockmeier2, 
Holly R. Hughes2, William D. Martin3, Anne S. De Groot1,3* 
 
1Institute for Immunology and Informatics, Department of Cell and Molecular Biology, University of 
Rhode Island, Providence, RI, USA 
2Virus and Prion Diseases Research Unit, NADC, USDA ARS, Ames, IA, USA 
3EpiVax Inc., Providence, RI, USA 
 
*Corresponding Author: Anne S. De Groot, M.D. 
   Institute for Immunology and Informatics 
Department of Cell and Molecular Biology  
University of Rhode Island 
Providence, RI, 02903, USA 
E-mail: dr.annie.degroot@gmail.com  
 45 
Abstract 
Swine influenza is a highly contagious respiratory viral infection in pigs that is responsible for 
significant financial losses to pig farmers annually. Current measures to protect herds from infection 
include: inactivated whole-virus vaccines, subunit vaccines, and alpha replicon-based vaccines. As is 
true for influenza vaccines for humans, these strategies do not provide broad protection against the 
diverse strains of influenza A virus (IAV) currently circulating in U.S. swine. Improved approaches to 
developing swine influenza vaccines are needed. Here, we used immunoinformatics tools to identify 
class I and II T cell epitopes highly conserved in seven representative strains of IAV in U.S. swine and 
predicted to bind to Swine Leukocyte Antigen (SLA) alleles prevalent in commercial swine. Epitope-
specific interferon-gamma (IFNγ) recall responses to pooled peptides and whole virus were detected in 
pigs immunized with multi-epitope plasmid DNA vaccines encoding strings of class I and II putative 
epitopes. In a retrospective analysis of the IFNγ responses to individual peptides compared to 
predictions specific to the SLA alleles of cohort pigs, we evaluated the predictive performance of 
PigMatrix and demonstrated its ability to distinguish non-immunogenic from immunogenic peptides 
and to identify promiscuous class II epitopes. Overall, this study confirms the capacity of PigMatrix to 
predict immunogenic T cell epitopes and demonstrate its potential for use in the design of epitope-
driven vaccines for swine. Additional studies that match the SLA haplotype of animals with the study 
epitopes will be required to evaluate the degree of immune protection conferred by epitope-driven DNA 
vaccines in pigs. 
 
Keywords: PigMatrix, epitope prediction, T cell epitope, Immunogenicity, Swine, influenza, influenza 
A virus, vaccine, immunoinformatics, Swine Leukocyte Antigen, SLA, iVAX, class I, class II  
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Introduction 
Swine influenza is a highly contagious respiratory viral infection in pigs that has a major impact on 
their health. In addition, influenza outbreaks are responsible for significant financial losses to pig 
farmers, large and small, on an annual basis [1]. The negative economic impact is due to weight loss, 
reduced weight gain and predisposition to other infections [2]. Clinical signs of the disease include 
fever, coughing, sneezing, nasal discharge, lethargy, and anorexia. The causative agent is influenza A 
virus (IAV), a negative-sense, single-stranded, segmented RNA virus of the Orthomyxoviridae family. 
Transmission is by direct contact and by aerosol [3]. As is true with IAV in humans, antigenic drift by 
accumulation of mutations and/or antigenic shift by reassortment with genes from other IAV subtypes 
results in the emergence of novel influenza viruses [4]. Human-to-swine ‘spillover’ events also 
contribute to the genetic diversity of swine IAV [5]. H1N1, H1N2, and H3N2 swine IAV subtypes are 
endemic and co-circulate in swine in the U.S. [6].  
Continual reassortment events led to the emergence of a novel triple-reassortant internal gene 
(TRIG) cassette that contains internal genes derived from human (PB1 gene), avian (PA and PB2 
genes) and swine (NS, NP, and M genes) IAV viruses [7]. The TRIG is conserved among swine IAV 
circulating subtypes and it seems to have the ability to combine with numerous hemagglutinin (HA) and 
neuraminidase (NA) genes, including those of human and swine origin leading to enhanced strain 
variability [7]. Thus, the primary antigenic component of swine IAV vaccines is HA, which has evolved 
to present antigenically distinct HA lineages including: (1) the classical swine lineages, H1α, H1β, 
H1γ, H1γ-2, H1pdm09; (2) lineages derived from human seasonal H1 viruses, H1δ1, H1δ2; and (3) H3 
cluster I-IV viruses [6,8,9]. This marked genetic diversity complicates the development of effective 
vaccines for pigs. 
The predominant type of vaccine used by pork producers consists of whole inactivated viruses 
(WIV), administered with adjuvant by intramuscular injection. HA is the primary target of protective 
antibody responses of this platform. These vaccines are problematic for three reasons. First, antibody 
induced by WIV vaccination does not provide significant protection against antigenically diverse strains 
of IAV [8,10]. Second, WIV vaccines have been linked to vaccine-associated enhanced respiratory 
disease (VAERD) in pigs when WIV vaccine and infecting strains are mismatched [11–13]. Lastly, 
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existing vaccines do not adequately address viral diversity.  
In contrast, cell-mediated immune responses to epitopes that are conserved across IAV strains 
have been shown, in a number of studies, to be protective against influenza. For example, human and 
mouse studies demonstrate that cell-mediated responses to conserved non-structural proteins can be 
broadly cross-reactive [14] and protective against variety of IAV subtypes [15]. Both CD4+ T helper 
cells (Th) and CD8+ cytotoxic T cells (CTL) contribute to clearance of IAV [16–18]. T cell help is also 
required for the development of high titers of strain-specific antibody [18]. In fact, memory T cell 
response improves vaccine efficacy against emerging IAV strains when cross-reactive helper T cell 
populations are present from prior infection and/or vaccination [19]. CTL responses have also been 
associated with viral clearance and reduced clinical severity in mice and humans [20,21]. Our group has 
been interested in the role of cross-conserved epitopes in protection against IAV in human populations, 
and has postulated that immunity to cross-conserved epitopes may have contributed to attenuation of 
morbidity in some age groups during the 2009 H1N1 IAV pandemic [22].  
Adaptive cell-mediated immune response depends on T cell receptor (TCR) recognition of 
peptides bound to major histocompatibility complex (MHC) molecules presented on the surface of 
cells. Immunoinformatics tools have accelerated the discovery of T cell epitope peptides and design of 
epitope-driven vaccines (EDV) for human IAV [23–26]. The lack of quantitative MHC binding data has 
limited the development of tools for swine, cattle, and other food animal species. We recently 
developed a new tool for swine epitope prediction (PigMatrix) that leverages the pocket profile method 
originally described by Sturniolo et al. [27]. We integrated the new swine MHC predictions into iVAX, 
the suite of tools for vaccine design that were validated in a number of pre-clinical studies of human 
vaccines [28,29]. This set of tools is particularly useful for identifying T cell epitopes that are conserved 
across subtypes of strains [30], which is relevant to develop a IAV vaccine for pigs. Having integrated 
the new matrices into this ‘in silico vaccine design’ platform, we were able to apply the PigMatrix 
version of iVAX to IAV.  
In this study, we used PigMatrix to predict class I and II T cell epitopes that are conserved in 
external and internal proteins from seven circulating IAV strains. We selected epitopes predicted to 
bind to SLA alleles that were previously reported to be prevalent in outbred U.S. swine populations 
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[31,32] and developed a prototype PigMatrix epitope-driven DNA-vaccine (PigMatrix-EDV) as a tool 
to evaluate immunogenic responses to highly conserved predicted epitopes in a swine IAV model. 
PigMatrix predicted peptides induced specific interferon gamma (IFNγ) recall responses in pigs 
immunized with the prototype PigMatrix-EDV encoding strings of class I and II putative epitopes. In 
addition, we performed a retrospective analysis to compare IFNγ responses to individual peptides (28 
class I and 20 class II peptides) with predictions specific to the SLA expressed in the study cohort. The 
results showed that cohort-specific predictions using PigMatrix, were particularly effective for 
identification of non-immunogenic peptides.  
 
Materials and Methods 
Sequences 
Gene sequences of proteins expressed by seven representative swine IAV (pandemic 
A/California/04/2009 (H1N1) (H1N1pdm09), A/swine/Illinois/5265/2010 (H1N1) (IL/10), 
A/swine/Ohio/511445/2007 (H1N1) (OH/07), A/swine/Minnesota/02011/2008 (H1N2) (MN/08), 
A/swine/Minnesota/A01301731/2012 (H1N2) (MN/12), A/swine/Texas/4199-2/1998 (H3N2) (TX/98), 
A/turkey/Ohio/313053/2004 (H3N2) (OH/04)) [33,34] were downloaded from the Influenza Virus 
Resource [35] (Supplemental Table 1).  
Conservation analysis 
The goal of the conservation analysis was to identify highly cross-conserved 9-mer peptides. Since 9-
mers fit into the SLA binding groove [36], proteins derived from IAV genomes were parsed into 9-mer 
frames overlapping by eight amino acids using the Conservatrix algorithm [30]. Nine-mer sequences 
were searched for identically matched segments among IAV strains, as previously described [28]. 
Resulting 9-mers were ranked by their conservation within the dataset.  
T cell epitope prediction 
Using the pocket profile method [27] and well-defined EpiMatrix binding preferences for human MHC 
pockets, we developed PigMatrix prediction matrices as previously described [29]. Matrices were 
designed based on the binding preferences of the best-matched Human Leukocyte Antigen (HLA) 
pocket for each SLA pocket. The contact residues involved in the binding pockets were defined from 
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crystal structures of SLA or HLA supertype alleles for class I and II, respectively. Allele selection was 
based on prior data indicating their prevalence in outbred swine populations [31,32]. Matrices were 
constructed to predict T cell epitope binding to class I (SLA-1*0101, 1*0401, 2*0101, and 2*0401) and 
class II (SLA-DRB1*0101, 0201, 0401, and 0601) SLA alleles. SLA-1*0401, 2*0401 and SLA-
DRB1*0201 were previously validated using published epitopes [29]. We also developed matrices for 
SLA alleles expressed in the study cohort (cohort-specific prediction) to perform a retrospective 
analysis.  
All highly conserved 9-mers resulting from Conservatrix analysis were scored for binding 
potential against the panel of SLA alleles. PigMatrix raw scores were standardized to Z-scores to 
compare potential epitopes across multiple SLA alleles. Peptides with Z-scores above 1.64 (the top 5% 
of any given sample of 9-mers) were identified as likely to be SLA ligands. The final selection of 
putative SLA class I-restricted epitopes was based on PigMatrix score (Z-score>1.64), SLA class I 
allele coverage (≥50%) and IAV strain coverage.  
Construction of immunogenic consensus sequences  
EpiAssembler was used to construct 16-25 amino acid length SLA-DRB1-restricted sequences that 
were highly conserved in IAV strains, promiscuous (predicted to bind to multiple alleles), and enriched 
for immunogenicity (immunogenic consensus sequences or ICS) [28]. The density of predicted binding 
motifs in each ICS was scored (i.e. cluster score) using ClustiMer [28]. The cluster score represents the 
deviation in predicted epitope content from baseline expectation based on random peptides [37]. ICS 
with cluster scores above 10 were considered to be high-quality clusters for inclusion in the prototype 
vaccine. Peptides were ranked based on cluster score and IAV strain coverage and the final selection of 
epitopes was made using the same three criteria described above for class I peptides. Highly 
hydrophobic peptides were excluded as these are known to be more technically difficult to synthesize 
and may be less soluble in aqueous solutions. 
Multi-epitope plasmid DNA vaccine engineering and production  
Predicted epitope sequences were concatenated to form two multi-epitope genes (one for SLA class I 
and one for class II epitopes). VaccineCAD [38] and a concatemer optimization algorithm 
(unpublished) were used to rearrange the peptides to avoid creation of novel epitopes at peptide 
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junctions and to search for transmembrane helices that might interfere with production of the epitope 
concatemer proteins. Both algorithms, VaccineCAD and the concatemer optimization algorithm, used 
PigMatrix to predict junctional epitopes.  
Transmembrane helices were predicted using TMHMM 2.0 [39]. In addition, where reordering 
did not sufficiently reduce the potential for junctional immunogenicity, a cleavage promoting spacer 
(‘AAY’) for class I-restricted constructs [40] or a binding inhibiting ‘breaker’ sequence (‘GPGPG’) for 
class II-restricted constructs [41], was introduced between peptides to optimize epitope processing. Two 
genes (one for class I and one for class II epitopes) predicted to have no transmembrane segments or 
junctional epitopes, were codon-optimized and synthesized by GeneArt (Life Technologies, NY, USA). 
Tandem stop codons were incorporated downstream of the epitope sequences. Class I and class II 
genes, respectively, were subcloned at predefined flanking restriction sites downstream of either a 
destabilizing UbiquitinA76 tag (UbA76) in pNTC8684-eRNA41H for proteasome targeting and a tissue 
plasminogen activator (TPA) leader sequence in pNTC8682-eRNA41H (Nature Technology 
Corporation, NE, USA) for secretory pathway targeting. High-purity plasmids for immunizations were 
prepared by Nature Technology Corporation, Inc. at research grade. Each plasmid underwent quality 
control testing including spectrophotometric concentration and A260/A280 ratio determination (1.97), 
restriction digest analysis to assure the presence of the multi-epitope genes, agarose gel electrophoresis 
determination of residual host RNA and DNA (none detected), and quantitative endotoxin testing (<2.0 
EU/mg). 
Peptide synthesis 
Peptides corresponding to putative epitopes in the DNA vaccine were synthesized using 9-
fluoronylmethoxycarbonyl (Fmoc) chemistry by 21st Century Biochemicals (Marlboro, MA). Peptide 
purity was >80% as ascertained by analytical reversed phase HPLC. Peptide mass was confirmed by 
tandem mass spectrometry. 
Immunizations 
Thirty-two, 3-week old outbred pigs from a high-health status herd known to be free of IAV were 
delivered to the USDA-National Animal Disease Center. To ensure that prior exposure to IAV resulting 
in immunity was absent, all of the pigs were screened for influenza A nucleoprotein antibody by ELISA 
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(MultiS ELISA, IDEXX, Westbrook, Maine) prior to the start of the study. All of the study pigs were 
treated with ceftiofur crystalline-free acid (Excede; Zoetis Animal Health, Florham Park, NJ, USA) and 
enrofloxacin (Baytril 100; Bayer HealthCare AG, Monheim, Germany) upon arrival to reduce bacterial 
contaminants. The experimental outline is summarized in Fig. 1. Pigs were randomly distributed into 
four groups of eight and housed in separate isolation rooms in animal biosafety level 2 (ABSL-2) 
containment. Three groups were vaccinated: (i) one group of eight pigs was vaccinated with the 
prototype PigMatrix DNA-vaccine as the initial prime vaccination, followed by two homologous boosts 
at 21 and 42 days post-initial vaccination (dpv) (PigMatrix-EDV); (ii) one group of eight pigs was 
vaccinated with empty DNA plasmids containing no epitopes (Sham); (iii) one group of eight pigs was 
vaccinated with commercially available FluSureXP® administered 21 days apart, according to the 
manufacturer’s directions (Zoetis Animal Health, Florham Park, NJ) (FluSure). FluSureXP® contains 
whole inactivated γ-cluster H1N1, δ1-cluster H1N1, δ2-cluster H1N1, and cluster IV H3N2 swine IAV 
viruses. The final group of eight non-vaccinated pigs served as controls (NV). The prototype PigMatrix-
EDV plasmids were thawed at 4°C overnight, combined and administered intramuscularly in the 
postauricular region of the neck by needle stick injection with 4 mg per DNA plasmid in 4 mL of Tris-
EDTA (TE) buffer (2 mL on right side and 2 mL on left side).  
Animal care 
Animals at the National Animal Disease Center (NADC) are cared for in accordance with the guidelines 
set forth in the “Guide for the Care and Use of Laboratory Animals” (National Academy Press, 1996) 
and in regulations and standards as promulgated by the Agricultural Research Service, USDA, pursuant 
to the Laboratory Animal Welfare Act of August 24, 1966, as amended. Animal studies are reviewed 
and approved by NADC’s Institutional Animal Care and Use Committee (IACUC). In addition, the 
IACUC is federally mandated to review, at least once every 6 months, the research facility's animal care 
program and physical facilities per USDA regulations and using the “Guide for the Care and Use of 
Laboratory Animals” as the basis for review. Full-time animal caretakers, technicians and supervisors 
and on-call veterinarians perform routine animal care, as well as weekend/holiday activities and 
respond to emergencies. NADC staff members who worked with the animals have backgrounds and 
continuing training in the appropriate, species-specific care and handling of research animals. Training 
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courses for animal staff include safe handling skills, animal welfare, specific procedures (e.g. bleeding), 
personal protective equipment (PPE) requirements, as well as proper handling and care and use of 
anesthetics and analgesics. For this study, animals were housed in an ABSL-2 facility (12 h light/dark 
cycle) during the course of the study, and humanely euthanized at the termination of the project with a 
lethal dose of pentobarbital (Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI). Protocols were in 
place to humanely euthanize any animals if unforeseen clinical disease presented, such as severe 
lameness or depression that results in recumbency with reluctance to stand, although that did not occur 
in this study (all animals in the study were terminated at the end of the experiment). Animal 
observations and feedings were completed at least twice daily by personnel who have been trained to 
look for signs of illness or abnormalities, at which time the veterinarian on-call and the principal 
investigator would have been notified.  
Measurement of IFNγ response by ELISpot assay  
At 42, 49 and 63 dpv, whole blood was collected by venipuncture and peripheral blood mononuclear 
cells (PBMC) were isolated as previously described [42]. The frequency of epitope-specific T cells was 
determined by porcine IFNγ enzyme-linked immunosorbent spot (IFNγ ELISpot) assay according to the 
manufacturer’s recommendations (R&D Systems, Minneapolis, MN). Wells were seeded with 2.5 x 105 
PBMCs and stimulated with pooled peptides at 10 µg/mL, whole H1N1pdm09 virus (WV) at a 
multiplicity of infection (MOI) of 0.5, pokeweed mitogen (PWM) at 1 µg/mL, or culture media in a 
final volume of 0.25 mL.  
Immune responses to the IAV epitopes contained in the vaccines were evaluated using PBMC 
from each of 32 study animals. To simplify the analysis, four pools of peptides were evaluated at all 
PBMC sampling points – one that included all 48 predicted peptides (All); a second pool that contained 
26 class I and II peptides predicted from internal proteins (Int); a third pool that contained 8 class II 
peptides predicted from external proteins (Ext-II); and a final pool that contained 14 class I peptides 
predicted from internal proteins (Int-I) (Fig. 2).  
In addition to the assays that were performed using pooled peptides, we evaluated epitope-
specific IFNγ responses to individual peptides at 49 dpv, using PBMC from pigs in groups PigMatrix-
EDV and FluSure (five from each group). Triplicate assays were performed for all peptide stimulations 
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and for controls. After 18 h of incubation in a 37°C humidified 5% CO2 incubator, the ELISpot plates 
were washed and developed according to the manufacturer’s recommendations. The ELISpot plates 
were then scanned in a CTL-ImmunoSpot S5 UV analyzer and spot counts were recorded using the 
ImmunoSpot software (Cellular Technology Ltd., Shaker Heights, OH). Results were recorded as the 
average number of spot forming cells (SFC) over background and adjusted to spots per 106 PBMCs. A 
response was considered positive if the number of spots was greater than or equal to 20 SFC over 
background per 106 PBMC. 
At the end of the study, pigs were SLA-typed using a low-resolution group-specific typing 
method [31] to evaluate SLA diversity and correlate epitope predictions with IFNγ responses. Select 
pigs were typed: two pigs from group NV, eight from Sham, seven from PigMatrix-EDV, seven from 
FluSure.  
Retrospective analysis 
IFNγ responses to individual peptides were compared to predictions using cohort-specific class I and II 
SLA PigMatrices. Class I peptides were scored and considered potential binders if the mean of 
significant Z-scores was above 1.64. Class II peptides with cluster scores above 10 were categorized as 
potential ligands. Experimentally, peptides that induced more than 20 SFC over background per 106 
PBMCs in at least one pig were considered positives. Based on the comparison of experimental results 
and predictions, peptides were divided into one of four categories (true positives, true negatives, false 
positives, and false negatives). True-positive peptides were predicted and validated in vitro as 
immunogenic, while true-negative peptides were predicted and biologically validated to be non-
immunogenic. False negative peptides were predicted to be non-immunogenic, yet produced a positive 
response; false positive peptides were predicted to be immunogenic, but produced no response in the 
IFNγ ELISpot assay. To evaluate the predictive performance of the matrices, we calculated the positive 
and negative predictive values (PPV and NPV, respectively) and area under the receiver operating 
characteristic (ROC) curve (AUC) using the sensitivity and 1 - specificity  (false positive rate) values. 
Antibody evaluation 
Pig serum was collected at 0 and 42 dpv for hemagglutination inhibition (HI) assay to assess antibody 
responses following vaccination as described previously [43]. Briefly, sera were heat-inactivated at 
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56°C for 30 min and then treated with a 20% suspension of kaolin (Sigma-Aldrich, St. Louis, MO) and 
subjected to adsorption with 0.5% turkey red blood cells (RBC) to remove nonspecific hemagglutinin 
inhibitors and natural serum agglutinins. The HI assays were then performed using H1N1pdm09 and 
OH/07 (γ-cluster H1) strains as antigen. Titers were determined using two-fold serial dilutions to detect 
the reciprocal endpoint of HI, log2 transformed and reported as the average geometric mean reciprocal 
titer for each group. Sera with titers <40 were considered HI negative or suspect.  
Statistical analysis 
IFNγ responses to restimulation treatments (pooled peptides and WV) in the PigMatrix-EDV group and 
the FluSure group, measured at 42, 49 and 63 dpv, were compared using a Kruskall-Wallis test 
followed by side by side comparisons of the groups using Dunn’s correction for multiple comparisons. 
The same test was used for comparison of HI antibody titers between groups at 42 dpv. Wilcoxon 
matched-pairs test was used to compare IFNγ responses within groups. To evaluate IFNγ responses to 
more than two restimulation treatments for a group at a specific timepoint and the effect of the boosts in 
the PigMatrix-EDV group, the Friedman test using Dunn’s correction was used. P values of less than 
0.05 were considered significant. All the statistical analyses were performed using GraphPad Prism 
software (GraphPad, San Diego, CA). 
 
Results 
Epitope selection 
A total of 28 class I and 20 class II peptides were down-selected for inclusion in the prototype 
PigMatrix-EDV IAV vaccine (Fig. 3), following immunoinformatic predictions. Peptides were selected 
based on predicted binding to class I (SLA-1*0101, 1*0401, 2*0101, and 2*0401) and class II (SLA-
DRB1*0101, 0201, 0401, and 0601) SLA alleles.  
Since external proteins (HA and NA) are highly variable, it was difficult to identify highly 
conserved potential epitopes. For this study, the minimum IAV strain coverage required for epitopes 
derived from HA and NA proteins was 25%. We selected epitopes to achieve the broadest possible 
coverage despite this constraint. In contrast, internal proteins are conserved due to the presence of the 
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TRIG cassette; therefore, the coverage threshold for peptides selected from internal proteins (M1, M2, 
NP, NS1, NS2, PA, PB1, PB1-F2, PB2) was 85%.  
Fourteen class I peptides were selected from external proteins and 14 peptides were selected 
from internal proteins. The mean Z-score of class I peptides was 2.87(1.03), [reported as mean(standard 
deviation)]; these are high-scoring peptides that are considered likely to be T cell epitopes. Twenty-four 
of the class I peptides (85.7%) were predicted to bind to four alleles. Eleven of the 14 class I peptides 
(78.6%) identified in the external proteins were >85% identical in at least three of seven IAV strains. 
Similar epitopes were selected to evaluate strain specificity; HA_1 and HA_2 differed by one amino 
acid, but HA_1 was 100% identical in four strains, whereas HA_2 was present only in one IAV 
(OH/07). NA_14 was identified in one IAV, but its sequence was 77.8% identical (7 of 9 amino acids) 
to NA_11, which was conserved in two other IAVs. Both peptides were predicted to bind to four class I 
SLA alleles. For the putative class I peptides derived from internal proteins, 11 of 14 (78.6%) were 
100% identical in the IAVs analyzed.  
Cluster scores for all the selected class II ICS were greater than 10. Eight of the 20 ICS were 
derived from external and 12 from internal proteins. Their lengths ranged from 16 to 25 amino acids. 
All the peptides had at least one 9-mer frame predicted to bind to at least three SLA class II alleles; 
80% (16 of 20 peptides) had at least one 9-mer predicted to bind to all four SLA class II alleles. From 
the external proteins, five of the predicted peptides were >85% identical in at least three IAV strains. 
Class II peptides derived from internal proteins were >85% identical in all seven IAVs, with exception 
of M_10 that had 84.2% identity (differed by 3 amino acids) with its counterpart in OH/04. Taken 
altogether, the immunoinformatics-predicted sequences represent a set of potentially broadly reactive 
swine influenza T cell epitopes. 
Epitope-driven DNA vaccine construction 
As a tool to evaluate epitope-specific responses to predicted peptides, we designed two prototype DNA 
vaccines; one containing class I-restricted epitopes and one containing class II-restricted epitopes 
(Supplemental Text 1). To minimize potential junctional immunogenicity of the class I construct, 
breakers (‘AAY’) were inserted at seven of 27 peptide junctions. In one case, a ‘spacers’ (‘GPGPG’) 
was introduced into the class II construct to disrupt the formation of junctional epitopes. Both 
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constructs were designed to avoid potential transmembrane domains. The DNA vaccine vectors also 
contained signal sequences to target the string of epitopes to the proteasome or the secretory pathway. 
These signal sequences, UbA76 for class I and TPA for class II, were of human origin; however, 
BLAST analysis showed that amino acid sequences from both were 99% and 71% identical, 
respectively, to their swine counterparts.  
T cell immunogenicity 
Epitope-specific responses to pooled PigMatrix-predicted peptides were demonstrated in immune recall 
IFNγ ELISpot assays using PBMC isolated at 42 (day of second boost), 49, and 63 dpv from animals in 
the PigMatrix-EDV and Sham groups (Fig. 4A). The four peptide pools (All, Int, Ext-II, and Int-I; Fig. 
2) used for restimulation induced statistically significant different responses between pigs vaccinated 
with PigMatrix-EDV and Sham (p<0.05). IFNγ responses measured in pigs from PigMatrix-EDV and 
FluSure groups were significatively different (p<0.05), with exception of restimulation with pool Ext-II. 
No significant differences were observed between pigs vaccinated with FluSure and Sham. In 
PigMatrix-EDV-vaccinated pigs, we expected class II epitopes to dominate in the immune response to 
external proteins, and class I epitopes to dominate the immune response to the internal proteins. 
Contrary to our expectation, the number of IFNγ SFC induced by pools of class II peptides from 
external proteins (Ext-II) and class I peptides from internal proteins (Int-I) was below 20, which was 
significantly lower (p<0.001) than responses to all peptides pooled together (All) and peptides derived 
from internal proteins (Int). SFC were not statistically different between All and Int pools (p=0.74). 
These results suggest that immune responses to class II predicted epitopes contained in internal IAV 
proteins dominate the PigMatrix-EDV-induced response.  
IFNγ SFC induced by restimulation with WV in PBMC from pigs in the PigMatrix-EDV group 
were also statistically different from Sham (p<0.05) at all three measured time points. This result 
suggests that T cells raised against epitopes contained in the prototype DNA vaccine recognize epitopes 
presented in whole virus stimulation in vitro.  
It is interesting to note that the IFNγ SFC induced by restimulation with All and Int pools were 
not statistically different from responses to WV in PBMC from the PigMatrix-EDV group, with the 
exception of responses at 49 dpv (All: 49 (32.34), Int: 43.57 (33.93), WV: 84.29 (47.92) SFC per 106 
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PBMC; p=0.02; Fig. 4A). This may suggest that the epitopes in the peptide pools were recognized by T 
cells that were responsible for the majority of T cell responses to WV, in vitro. Differences in the 
antigen presentation processes (in vitro) for WV and peptides may explain the differences at 49 dpv 
[44]. Alternatively, WV RNA could have played a role in the expansion of T cell responses in vitro 
[45]. It is also possible that the IFNγ ELISpot assay only sampled a fraction of the antigen-specific cells 
present in the PBMC after in vitro stimulation; thus, technical limitations may explain comparable 
responses between pooled peptides and WV restimulation.  
Interestingly, IFNγ responses to WV restimulation did not significantly differ in PigMatrix-
EDV (73.84 (54.48)) and FluSure-immunized (127.55 (175.86)) pigs (Fig. 4A). Note that the mean and 
high variability in the FluSure group was due to consistently high recall responses in PBMC from one 
“high responder pig” (FS-442; Fig. 4A, marked with +) at the three time points tested (mean IFNγ SFC 
per 106 PBMC excluding this pig was 58.52 (51)). Thus, the epitope-based vaccine elicited consistent 
IFNγ responses equivalent to those induced by a tetravalent commercial WIV vaccine.  
Boost immunizations in the PigMatrix-EDV group did not result in significant changes in the 
number of IFNγ SFC when PBMCs were restimulated with All, Int pools and WV (Fig. 4A and 
enhanced in Fig. 4B).  
Restimulation with individual peptides 
As noted before, we suspected that recall response to peptide pools in PBMC from PigMatrix-EDV 
vaccinated pigs was primarily driven by class II predicted epitopes derived from internal IAV proteins. 
This observation was confirmed by evaluating IFNγ responses to individual peptides a week after the 
second boost (49 dpv) (Fig. 4C and 4D). PBMC from pigs immunized with PigMatrix-EDV or FluSure 
(five from each group) were restimulated with individual class I and II peptides. Four class I peptides 
(derived from external proteins) and seven class II peptides (derived from internal proteins) induced 
more than 20 IFNγ SFC per 106 PBMC over background for at least one pig immunized with PigMatrix-
EDV. At 49 dpv, none of the peptides induced significant responses in PBMC from the five FluSure-
vaccinated pigs tested. Note that the high responder pig from the FluSure group, who registered the 
highest responses to peptide pool restimulation at 42, 49, and 63 dpv (FS-442, Fig. 4A, marked with +), 
was not included in the individual peptide restimulation assays. 
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Retrospective analysis using cohort-specific predictive matrices 
Putative epitopes were predicted for binding to a set of SLA alleles prevalent in outbred swine 
populations [31,32]. To determine if those alleles were expressed in the study cohort, SLA types were 
determined at low resolution [31,32] at the end of the study for eight pigs from the Sham group, seven 
from PigMatrix-EDV, seven from FluSure, and two from NV group (Supplemental Table 2). By 
chance, none of the SLA-typed pigs tested in individual peptide ELISpot assays (Table 1), expressed 
any of the alleles used for epitope predictions. A pig that responded to four class I peptides (PigMatrix-
EDV-427) was not SLA-typed; thus, no correlation of immune recall and epitope predictions could be 
made between the existing matrices and these ELISpot data. 
To retrospectively evaluate the IFNγ responses to individual peptides and the association with 
specific SLA haplotypes, we developed class I and II matrices specific for the most frequent SLA-1, 
SLA-2, and SLA-DRB1 alleles expressed in the actual cohort (cohort-specific, Table 1). Although 
certain low-resolution results were ambiguous, we can make some assumptions based on common 
associations. For SLA class II, based on common association with DQB1 and DQA alleles [32], we 
expect that SLA-DRB1*0401-02 is likely to be DRB1*0402 and DRB1*06XX is likely to be 
DRB1*0602. These two alleles were expressed in 79% of the typed pigs. For the rest of the frequently 
expressed alleles, we developed XX01 as the default matrix (e.g. for DRB1*07XX, we developed SLA-
DRB1*0701 prediction matrix). Thus, we developed cohort-specific prediction matrices for SLA-
1*0801, 1*1201, 1*1301, 2*0501, 2*1201, DRB1*0402, 0602, 0701, and 1001.  
The initial set of peptides was selected because they were predicted to bind promiscuously to 
the SLA alleles that are prevalent in outbred swine populations (SLA-1*0101, 1*0401, 2*0101, 2*0401, 
DRB1*0101, 0201, 0401, and 0601). However, a reduced number of peptides were predicted to bind to 
the actual, cohort-specific alleles, once this information was available (Fig. 5). For example, none of the 
peptides were predicted to bind the most frequently expressed SLA allele for this cohort (SLA-1*0801). 
Cohort-specific predictions yielded a total number of hits per allele, for this set of peptides, that was 
41.7% lower than the initial prediction based on reported prevalent alleles. Despite the fact that the 
predictions did not correspond well with the sampled SLA, 23 PigMatrix-EDV peptides were still 
predicted to bind to alleles in the cohort, explaining the responses observed in the pool restimulation. 
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This also suggests that initial predicted promiscuity (i.e. ability for a peptide to bind to multiple alleles) 
present in selected peptides extends to additional cohort-specific alleles. 
Cohort-specific class I predictions 
Further evaluation of the cohort-specific predictions revealed that PigMatrix predictions for the 28 class 
I peptides (Fig. 5, top) had high sensitivity (1.0) and NPV (1.0), and moderate specificity (0.63). 
Cohort-specific prediction correctly classified 15 of the 24 peptides that were non-immunogenic. In 
terms of immunogenic peptides, four out of four were predicted as immunogenic, though nine false 
positive peptides were also observed, contributing to the low PPV (0.31).  
To evaluate the predictive performance of the cohort-specific prediction, we built an ROC 
curve and then calculated the AUC (a value of 1 corresponds to a perfect prediction and 0.5 to a random 
prediction). The AUC was 0.81, which shows that predictions for cohort-specific alleles had high 
predictive power. However, the size of the dataset may have influenced these results; prospective 
studies on larger cohorts of pigs would be required to validate this observation.  
Cohort-specific class II predictions 
Predictions targeting cohort-specific SLA alleles showed that peptides had limited binding likelihood. 
Cohort-specific cluster scores were lower for 18 out of 20 peptides compared to cluster scores for SLA 
alleles reported as prevalent in outbred pigs (SLA-DRB1*0101, 0201, 0401, 0601; Fig. 5, bottom). 
Note that the cohort-specific cluster score of false negative peptide M_10, which calculated for four 
SLA-DRB1 alleles (DRB1*0402, 0602, 0701, and 1001), was below 10 (the threshold we set for 
potential binders), but it was still predicted to bind to the two SLA-DRB1 alleles (DRB1*0602 and 
1001) expressed by PigMatrix-EDV SLA-typed pigs (pig PigMatrix-EDV-432 only expressed SLA-
DRB1*1001), and corresponded to the positive responses observed. 
Cohort-specific class II predictions (Fig. 5, bottom) had high sensitivity (0.86) and NPV (0.90), 
and moderate specificity (0.69) and PPV (0.60). They also showed high predictive power (AUC 0.77) 
for the set of 20 class II peptides. Nine of the 13 peptides that were non-immunogenic were correctly 
predicted and six out of seven immunogenic peptides were predicted as immunogenic. Only four 
peptides that were predicted to be immunogenic were non-immunogenic in T cell assays.  
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Overall, the retrospective analysis of 48 peptides using predictions for cohort-specific SLA 
alleles showed high sensitivity, moderate-to-high specificity and high predictive power for both class I 
and II SLA alleles. Predictions were particularly effective identifying non-immunogenic peptides as 
demonstrated by their high NPVs. Cohort-specific predictions correctly identified 24 out 37 non-
immunogenic peptides and 10 out of 11 positive peptides. Still, it is important to mention that the 
limited number of peptides makes these results less robust. A larger dataset of peptides will be required 
to confirm the predictive power of the matrices. 
Antibody responses  
FluSureXP® induced detectable HI antibody against OH/07 γ-cluster virus, with no cross-reactivity to 
the H1N1pdm09 virus with serum collected 42 dpv (Table 2). HI antibody titers against OH/07 were 
significantly different from Sham and PigMatrix-EDV (p<0.001). PigMatrix-EDV did not induce a 
detectable positive HI antibody response against H1N1pdm09 or OH/07 at 42 dpv, which is not 
surprising, as the T cell epitopes were not expected to encode B cell epitopes.  
 
Discussion 
In this study, PigMatrix, an immunoinformatics tool for predicting swine T cell epitopes, was used to 
identify class I and II epitopes highly conserved among seven IAV strains representative of those 
prevalent in U.S. swine. To evaluate the immunogenic potential of the predicted peptides, IFNγ SFC 
recall responses were measured in pigs vaccinated intramuscularly with prototype DNA vaccines 
(PigMatrix-EDV) encoding strings of class I and II epitopes or a commercially available swine IAV 
vaccine. Recall responses induced by pooled peptides in PBMCs isolated from pigs vaccinated with 
PigMatrix-EDV were significantly greater than responses in pigs vaccinated with empty plasmids. 
Furthermore, PigMatrix-EDV-vaccinated pigs responded to WV (H1N1pdm09) restimulation, showing 
that the epitope-based immunization gave rise to T cells that are cross-reactive with epitopes present in 
the whole virus in vitro. In addition, overall responses to WV restimulation were comparable to those 
induced by All and Int pools. Moreover, epitope-specific recall responses to WV in pigs immunized 
with a prototype epitope-based vaccine were similar to responses in pigs immunized with the 
commercial vaccine.  
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A challenge study was conducted to evaluate protective efficacy of PigMatrix-EDV. Pigs were 
intranasally challenged with H1N1pdm09 virus, but due to age at challenge and route of challenge, 
pathology and viral load in non-vaccinates was limited, so assessing protection overall in vaccinates 
was also limited. There was no evidence of enhanced lesions (VAERD) in vaccinates, and outcome in 
DNA-vaccinates and FluSure vaccinates was similar (data not shown). Future work aimed at assessing 
efficacy of the DNA approach is warranted, and further consideration will need to be given to animal 
age, route of challenge, challenge strain, and SLA haplotype of animals to adequately evaluate the 
vaccine. Ideally, a group of pigs challenged with influenza A virus should be included to evaluate 
whether the predicted T cell epitopes are also induced during natural infection. 
Our initial set of alleles used for T cell epitope prediction did not correspond well with the 
cohort ultimately selected. For this prospective study, we developed predictions for SLA alleles that had 
been reported to be frequently expressed in outbred swine populations [31,32]. However, post hoc SLA 
typing results showed that those alleles were not prevalent in pigs in the study. Still, some peptides 
induced IFNγ SFC responses, demonstrating the initial set of alleles positively predicted promiscuous 
epitopes. This has significant implications for vaccine design because identification of epitopes capable 
of binding to multiple SLA alleles limits the number of epitopes required to cover an SLA diverse 
population. A retrospective analysis using cohort-specific alleles showed that some of the peptides were 
predicted to bind to the new SLA alleles, although the set of peptides overall was not optimally matched 
to the cohort. These results indicate that selecting epitopes for promiscuity, when pig SLA-typing is not 
available, may be relevant because conservation of binding likelihood in a promiscuous epitope may 
extend to additional (untested) alleles. While it is clear that we will need to expand the set of alleles for 
future vaccine designs, this finding suggests that using immunoinformatics tools to identify 
promiscuous T cell epitopes can contribute to those future designs [26,46]. 
Designing epitope-based vaccines for pigs is hindered by the lack of information on SLA 
diversity in the U.S. swine population. A systematic evaluation of the SLA frequency will make it 
possible to develop and apply predictions for the most representative SLA alleles (supertypes) [47,48] 
to vaccine designs that cover a high percentage of the swine population. In addition, a more streamlined 
(i.e. rapid, high resolution, commercially available) approach to SLA typing would significantly 
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improve the ability to study T cell responses to influenza and other economically important diseases 
such as porcine reproductive and respiratory syndrome (PRRS) and porcine epidemic diarrhea (PED).  
In this study, class II peptides from internal proteins were highly conserved (identity >85%) 
across all the analyzed strains and were shown to be the most immunogenic. Internal proteins from IAV 
are conserved across multiple strains because of the prevalence of two evolutionary lineages, H1pdm09 
and TRIG, in the U.S. swine population [33]. We note that the genome sequences of the strains in the 
commercial vaccine are not available; however, it is likely that the internal epitopes were from the 
TRIG cassette (all seed strains predate introduction of H1N1pdm09 into the swine population). For this 
reason, it was interesting to see that PBMC from pigs immunized with FluSure had more limited IFNγ 
SFC responses to peptide pools, even though the pigs expressed similar SLA alleles to pigs in the 
PigMatrix-EDV group. This observation supports the hypothesis that epitope-based vaccines promote 
more efficient processing and presentation of their own epitopes as compared to whole-protein-based 
vaccines. Similar results were observed in mouse studies using T cell epitope-based DNA vaccines for 
H. pylori, where 33 out of 50 peptides stimulated more than 50 IFNγ SFC in splenocytes from the group 
vaccinated with an epitope-based DNA vaccine, but only two of the peptides were recognized in the 
group vaccinated with the whole bacteria lysate [49]. If epitope-based vaccines are able to induce 
immune responses to more individual epitopes than whole pathogen formulations containing the same 
epitopes, selection of the right epitopes, with the right breadth of SLA coverage, may lead to the 
development of more efficacious vaccines than currently exist [49]. 
Contrary to our expectations, we observed that IFNγ recall responses to class I peptides were 
restricted to external proteins, while responses to class II peptides were focused on epitopes derived 
from internal proteins. In human studies, most cross-reactive CD8+ (class I) and CD4+ (class II) T cell 
epitopes are derived from internal IAV proteins [14,50]. Compared to class I epitopes derived from 
internal proteins, HA- and NA-specific class I epitopes are said to be rare [51], but a few SLA-restricted 
HA and NA class I peptides have been reported [36,52]. In this study, the four class I peptides that 
induced IFNγ responses were derived from HA and NA. Sequence alignments using BLAST 
demonstrated that these peptides are conserved in different swine IAV strains. In humans, class II 
epitopes derived from HA and NA have also been reported [14,22,53], but none of the potential 
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epitopes from these antigens predicted by PigMatrix elicited measurable responses in the PigMatrix-
EDV group (Fig. 4D). The seven class II peptides recognized by PBMC in this study were derived from 
internal proteins (M, NP, PA, and PB). Similar to class I peptides, these peptides are conserved in IAVs. 
Previous studies have shown that cross-reactive T cell responses to conserved epitopes may provide 
broader protection against diverse strains than antibodies that target variable antigens [15,22].  
We searched the Immune Epitope Database (www.iedb.org) for swine influenza T cell epitopes 
and found that substrings of the predicted class II peptides NP_1, PA_7, PB_8, and M_12 have been 
reported to induce positive T cell responses, as measured by different methods (e.g. IFNγ ELISpot, 
tetramer staining, intracellular cytokine staining), for at least one human MHC class II allele. The 
published epitopes were derived from H1N1, H5N1, and H2N2 IAV strains. Thus epitopes that induce 
T cell responses in both human and pigs can be identified. Additionally, these epitopes may contribute 
to heterosubtypic cell-mediated responses against zoonotic IAV. 
We did not expect that the epitope-based vaccine would induce antibodies, and indeed, 
PigMatrix-EDV did not induce HI antibodies that reacted to OH/07 or H1N1pdm09. While the 
commercial vaccine induced antibodies against OH/07, they did not cross-react with H1N1pdm09. The 
commercial vaccine contains four IAV strains (H1γ, H1δ1, H1δ2 H1N1 viruses, and one cluster IV 
H3N2 virus). OH/07 is an H1γ virus, which explains the positive HI response to this virus.  
In conclusion, observed epitope-specific IFNγ recall responses demonstrate the potential for 
PigMatrix to predict conserved, promiscuous and immunogenic T cell epitopes. Further studies will 
evaluate the utility of PigMatrix for designing epitope-driven vaccines for swine. Epitope-driven T cell 
responses may not fully prevent IAV infection, but could reduce viral burden, as was observed for the 
2009 H1N1 outbreak [22]. Rapid viral clearance and lower morbidity are important objectives for swine 
IAV vaccines, since current vaccines do not provide complete protection against variant strains. 
Moreover, epitope prediction tools could be used to assess the potential for existing commercial vaccine 
strains to protect against newly emergent strains of IAV. Improved immunoinformatics tools that target 
a comprehensive set of SLA alleles may contribute to the development of vaccines against other 
prominent swine diseases and provide a significant positive impact for pig health and swine producers.  
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Table 1. Low resolution SLA-type alleles of pigs tested in individual peptide ELISpot assays.  
  SLA class Ia SLA class IIa 
Group Pig SLA-1 SLA-2 DRB1 
PigMatrix-EDV 429 08XX,12XX,1301  0901-02,12XX  06XX,10XX  
 431 08XX,12XX,1301  05XX,10XX  06XX,10XX  
 432 08XX  05XX,10XX  10XX  
 433 08XX,12XX,1301  0901-02,12XX  06XX,10XX  
FS 435 1103,12XX,1301  10XX,jh02  06XX  
 436 08XX  05XX,12XX  0401-02,10XX  
 437 12XX,1301  10XX 06XX  
 439 08XX  12XX  0401-02  
 441 1103,12XX,1301  10XX,jh02  06XX  
aOnly loci for which prediction matrices were developed are shown. 
 
 
Table 2. Geometric mean reciprocal titers of HI antibodies to different virus in sera collected at 
42 dpv. 	 Viral	antigen*	
Vaccine	group	 H1pdm09	 OH/07	NV	 7	 6	Sham	 6	 6	PigMatrix-EDV	 10	 6	FluSure	 8	 104	
*Titers <40 are considered negative or suspect. 
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Fig. 1. Experimental outline. 		
 
 
Fig. 2. Peptide pools tested.All: 48 peptides. Int: 26 class I and II peptides predicted from internal 
proteins. Ext-II: Eight class II peptides predicted from external proteins. Int-I: 14 class I peptides 
predicted from internal proteins. 
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Fig. 3. Class I and II predicted peptides. Peptides were selected based on predicted binding to class I 
and class II SLA alleles and conservation in IAV strains. The identity percentage between peptides and 
IAV strains is shown (100% dark gray, 99% - 85% gray, and <85% white). The Peptide ID is coded to 
the source protein. Sequences not available are marked with -. 
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Fig. 4. Peptide immunogenicity measured by IFNγ ELISpot. (A) PBMC (2.5 x 105) isolated at three 
different time points (42, 49, and 63 dpv) from pigs immunized with empty plasmid (Sham), epitope-
driven DNA vaccine (PigMatrix-EDV) and commercial vaccine (FluSure) were restimulated with 
pooled peptides (All, Int, Ext-II, and Int-I) at 10 µg/mL and whole virus (WV). The number of epitope-
specific IFNγ spot forming cells (SFC) induced by the pools were measured using ELISpot assays. 
“High responder pig” (FS-442) is marked with +. (B) To evaluate vaccine boost effect, IFNγ responses 
to pooled peptides were measured at three different time points. For A and B, SFC over background, 
adjusted to spots per 106 of PBMC seeded, are represented with bars indicating means and error bars 
indicating standard deviation (SD). Pooled peptide responses showing statistical significance when 
compared to Sham are indicated: **p<0.01, *p<0.05. Significant statistical difference for PigMatrix-
EDV between restimulations at 49 dpv is also shown. Same colors and shapes are used in both figures. 
(C) PBMC from pigs vaccinated with PigMatrix-EDV and FluSure were restimulated with individual 
class I peptides and (D) class II peptides one week after the second boost (49 dpv). For C and D, SFC 
over background per 106 PBMC are shown. A response was considered positive if the number of spots 
was greater than or equal to 20 SFC over background per 106 PBMCs (dashed line).  
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Fig. 5. Comparison between prediction for prevalent and cohort-specific SLA alleles. Peptides 
were predicted to bind to a set of previously reported class I and class II SLA alleles prevalent in the 
U.S. swine population (prevalent). Based on low-resolution SLA-typing results, those alleles were not 
represented in the studied pigs. Prediction matrices were developed to predict binding potential of 
peptides to the most frequent SLA alleles found in the cohort (cohort-specific). (Top) Mean of 
significant Z-scores (above 1.64) over prevalent class I SLA alleles (SLA-1*0101, 1*0401, 2*0101, and 
2*0401) and cohort-specific (SLA-1*0801, 1*1201, 1*1301, 2*0501, and 2*1201) are shown for each 
peptide. Peptides with a mean of significant Z-scores above 1.64 (dashed line) are considered potential 
binders. (Bottom) Cluster scores calculated for prevalent class II SLA alleles (DRB1*0101, 0201, 0401, 
and 0601) and cohort-specific alleles (DRB1*0402, 0602, 0701, and 1001) are shown for each peptide. 
Cluster scores above 10 (dashed line) are considered as potential binders. Based on the retrospective 
evaluation, peptides were classified in four categories (TN: true negatives, TP: true positives, FN: false 
negatives, and FP: false positives). AUC, Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) are shown.  
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Abstract  
Background: Hemagglutinin (HA) is the most variable antigen of swine influenza A viruses (IAV) and 
the major target of protective antibody responses; hemagglutination inhibition (HI) antibody titers are 
widely used to predict vaccine cross-protection. T cell epitopes that are cross-conserved between IAV 
strains also play a role in protection. 
Objective: Determine the association of T cell immunogenic potential with vaccine-induced protection. 
Methods: We developed a method for T cell epitope content comparison (EpiCC) and used it to 
compare field H1 swine IAV HAs to HAs in a commercial vaccine. The PigMatrix algorithm was used 
to predict T cell epitope content for twenty-three HA sequences representing the major H1 swine IAV 
phylo-clusters. The T cell epitope-based relatedness (EpiCC scores) between vaccine and field viruses 
was calculated and compared to experimental data from previous efficacy studies where immunization 
induced protection in the absence of cross-reactive HI antibodies. 
Results: A comparison of HA T cell epitope content of the γ-cluster H1 vaccine virus to viruses used in 
homosubtypic challenge studies yielded a relatedness score associated with protection, assuming 
minimal epitope variation of other viral antigens. 
Conclusion: The T cell epitope content relationship deduced from vaccine efficacy studies evaluated 
here may support the hypothesis that T cells contribute to vaccine efficacy. EpiCC could be used 
retrospectively and prospectively to estimate the immunologic relationship of genetically and 
antigenically variable viruses assessed in vaccine efficacy studies. EpiCC may complement studies of 
HI cross-reactivity and phylogenetic data for the prospective selection of influenza strains in flu vaccine 
development. Complete viral proteome EpiCC analysis would provide more comprehensive information 
to estimate vaccine efficacy. 
 
Keywords: Computational immunology, hemagglutinin, SLA, swine influenza H1 viruses, vaccine 
efficacy, T cell epitope content comparison, T cell epitope prediction. 
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Introduction 
Influenza A viruses (IAVs) cause a highly contagious respiratory disease in swine that has a significant 
economic impact on the pork industry [1]. Hemagglutinin (HA) and neuraminidase (NA) are the two 
major surface glycoproteins that define IAV subtypes and play a key role in antigenicity, pathogenesis, 
host range, and diagnosis. The segmented IAV genome allows for antigenic shift by reassortment of 
RNA segments from different viral strains infecting the same cell, generating novel viruses [2]. 
Antigenic drift due to accumulation of mutations in HA and NA also contributes to the remarkable 
diversity of IAVs [2].  
Currently, H1N1, H1N2 and H3N2 are the predominant IAV subtypes co-circulating in the 
North American swine population. These subtypes are further subdivided based on the genetic and 
antigenic properties of HA. For H1 viruses, seven distinct genetic phylo-clusters (α, β, γ, γ-2, δ1, δ2 and 
pandemic (pdm09)), have been identified [3]. The HA gene of α, β γ, and pdm09 cluster viruses is most 
similar to classical swine H1N1 (cH1N1) [3]. HA from human-origin δ viruses can be differentiated in 
two subclusters, δ1 and δ2 [4]. Based on the antigenic properties of HA, serological cross-reactivity 
between H1 clusters similar to cH1N1, can be variable, but there is limited to no cross-reactivity 
between these viruses and the even more divergent δ cluster viruses [3,5]. This diversity presents a 
challenge to pork producers, veterinarians and vaccine manufacturers who wish to match vaccine 
strains to relevant field strains.  
Most of the North American commercial vaccines against swine IAV contain inactivated 
viruses. The predominant antibody responses induced by these vaccines is to the HA proteins [1,6]. 
Therefore, hemagglutination-inhibiting (HI) antibody titers as well as genetic information of HAs are 
used to evaluate the potential for one vaccine to protect against variant strains [6]. However, based on 
lung lesions and viral titers, full or partial protection of pigs can be observed following vaccination with 
inactivated commercial vaccines, in the absence of antibody cross-reactivity [1,6–12]. 
 Protection in the absence of neutralizing antibodies is presumed to be due to cell-mediated 
immunity (CMI) to cross-conserved T cell epitopes [13,14]. Cross-conserved T cell epitopes have been 
associated with protection against influenza in other contexts. For example, in humans, immunity to 
cross-conserved epitopes during the 2009 H1N1 IAV pandemic may have contributed to attenuation of 
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morbidity in some age groups [13,15]. In a previous study, we showed that a DNA vaccine based on 
eight HA T cell epitopes and one NA epitope conserved between seasonal and pdm09 lowered lung 
viral loads in HLA-DR3 transgenic mice challenged with pdm09 [16]. Cross-protection induced by 
conserved antigens does not induce complete protection against infection, but reduces mortality, 
morbidity, virus replication, and viral shedding [17,18]. CMI depends on the activation of cytotoxic T 
lymphocytes (CTL, CD8) and T helper (Th, CD4) lymphocytes when their T cell receptors (TCR) 
recognize T cell epitopes presented by class I or class II major histocompatibility complex (MHC) 
molecules on the surface of antigen presenting cells or infected cells [19]. CTL kill virus-infected cells, 
whereas Th responses support memory CD8 T cell development and provide help to B cells for high-
affinity, neutralizing antibody responses [13]. 
Here, we describe an approach for T cell epitope content comparison (EpiCC) that compares 
putative class I and II epitopes to assess relatedness across antigens and predict potential vaccine 
efficacy. Using this method, we evaluated whether T cell epitope relatedness could explain protection 
against heterologous IAV challenge (in the absence of cross-reactive antibodies). EpiCC uses 
PigMatrix, an algorithm that predicts class I and II T cell epitopes specific to swine MHC (Swine 
Leukocyte Antigen, SLA) alleles [20]. PigMatrix and additional tools in the iVAX toolkit [21] have 
been used to prospectively identify conserved T cell epitopes from different H1 phylo-clusters [21,22]. 
We applied PigMatrix and EpiCC to HA proteins from 23 swine IAV strains representing the major H1 
phylo-clusters circulating in the North American swine population. Since the internal genes in North 
American swine influenza have remained prevalent and conserved since 1998 (due to the emergence of 
the triple reassortant internal gene (TRIG) cassette), we assumed minimal T cell epitope differences 
therein and focused on the critical and most variable swine IAV antigen, HA [3,23,24]. Comparing the 
results of vaccine efficacy studies with the IAV EpiCC scores, we identified a level of T cell epitope 
related for a γ-cluster H1 vaccine virus associated with protection.  
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Methods 
Sequences 
HA sequences from 23 H1 IAV strains were included in the analysis (Table 1). Twenty sequences were 
from swine H1 viruses representing α, β, γ, γ-2, δ1, δ2 and pdm09 phylo-clusters and three were from 
the H1 vaccine viruses (γ, δ1 and δ2 H1 phylo-clusters) in FluSure XP® (FS; Zoetis Inc, Florham Park, 
NJ). Phylogenetic analysis was performed using MEGA 7 [25]. HA nucleotide sequences were aligned 
with MUSCLE and an evolutionary tree was inferred using the Maximum likelihood method with 500 
bootstrap replicates. 
MHC binding prediction 
The HA amino acid sequences of the 23 IAV strains were screened using PigMatrix [20]. PigMatrix 
parses sequences into 9-mers and assesses the binding potential of each 9-mer i to SLA class I and II 
alleles. For each individual allele a in a set of MHC alleles A, PigMatrix raw scores r are normalized to 
Z-scores using the average µ and the standard deviation σ of scores calculated for 100 000 random 9-
mers.  
!(!)! = ! − !!  
In this normalized set of scores for each SLA allele, 9-mers with Z-scores above 1.64 comprise the top 
5% of sequences with significant SLA binding potential. Increasing Z-scores correlate with higher 
MHC binding probability. 
  The distribution of SLA alleles among pig herds in the United States is unknown. Binding was 
therefore predicted to a set of SLA class I and II alleles that were frequently expressed in a cohort tested 
in a previous study (SLA-I: SLA-1*0801, 1*1201, 1*1301, 2*0501, 2*1201, 3*0501, 3*0601, and 
3*0701; SLA-II: SLA-DRB1*0201, 0402, 0602, 0701, and 1001) [22]. 
  Since data are lacking on breadth of coverage for SLA, a comparison was performed using 
HLA alleles. The breadth of coverage of HLA alleles (i.e. the ability to cover a global population) is 
known [26,27]; therefore, the HLA-restricted T cell epitopes that could be identified in these IAV 
sequences was quantified and compared to the epitopes uncovered in the sets of SLA alleles. The 
following HLA class I and class II supertype alleles were used for this comparison, HLA-I: A*0101, 
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A*0201, A*0301, A*2402, B*0702, and B*4403, and HLA-II: DRB1*0101, 0301, 0401, 0701, 1101, 
1301, and 1501 [28].  
T cell epitope content comparison 
The EpiCC algorithm assesses the relatedness of a protein sequence of a strain s and a protein sequence 
of a vaccine strain v based on a comparison of their T cell epitope content, predicted for the same set of 
MHC alleles A. For any comparison, the predicted epitope content can be either shared between 
sequences or unique to the strain or to the vaccine. Thus, the score of the comparison between the 
epitope content of s and v (EpiCC score or T cell epitope-based relatedness) considers scores of shared 
and unique epitopes (Fig. 1).  
  Intuitively, the epitope content of a protein depends on its epitope density. So, if a ‘high 
epitope density’ protein is compared to a highly similar protein and many of their epitopes are 
conserved or shared between the two strains, the scores of shared epitopes will be high; consequently, 
the score of the comparison of their epitope content (EpiCC score) will also be high. The score will be 
even higher if the 9-mer epitopes are predicted to bind with high probabilities to alleles in the set A. 
 We hypothesized that if epitopes in a vaccine match the epitopes in the challenge strain, and 
vaccine and strain unique epitopes are rare, the memory T cells induced by the vaccine are likely to 
cross-react with epitopes from the challenge strain. The model assumes (1) a naive immune system, (2) 
the vaccine does not induce memory T cells to challenge strain unique epitopes, and (3) the immune 
response to the vaccine could be biased to vaccine unique epitopes [29]. Consequently, the EpiCC score 
of two sequences is improved by the presence of shared epitopes and is lowered when strain and 
vaccine unique epitopes are present.  
 The EpiCC score is calculated using T cell epitope predictions for s and v. Each 9-mer i ∈s is 
compared to a corresponding 9-mer j ∈v. The pairs of 9-mers i,j are determined from a local alignment 
of s and v sequences using the Smith-Waterman algorithm from EMBOSS [30]. For i,j where one of the 
9-mers has a gap in position one, that 9-mer is considered “nonexistent”, i.e. excluded from 
comparison.  
 For each i,j and each allele a ∈A, the score of a shared T cell epitope S(i,j)a is computed only 
for cross-conserved epitopes (i.e. i,j with identical residues that face the TCR and predicted to bind to 
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allele a). We reasoned that epitopes with identical TCR-facing residues (TCRf), that are also predicted 
to bind to the same MHC allele, are more likely to induce cross-reactive memory T cells. This is a 
simple assumption because a TCR can recognize peptides with different TCRf [31], but it is a 
conservative initial approach to define potential cross-reactive epitopes [32]. For class I T cell epitope 
comparison, we assumed that i and j are cross-conserved, and potentially cross-reactive, if they have 
identical residues in positions 4, 5, 6, 7, and 8 and are predicted to bind to a, regardless of differences 
on their MHC-facing amino acids. For class II, amino acids in positions 2, 3, 5, 7, and 8 were 
considered TCRf. Positions were selected based on published analysis of peptide-MHC-TCR crystal 
structures [33]. S(i,j)a is calculated using predicted binding probabilities as follows:  ! !, ! ! = ! ! ! ∙ ! ! ! 
where p is the cumulative probability in the Normal distribution for the Z-score. Since the binding of i 
and j to allele a are independent, S(i,j)a, the probability of them both occurring, is the product of the 
probabilities of each occurring (i.e. joint probability). 
 The score of a unique epitope U(i,j)a is determined for non-cross-conserved epitopes based on 
binding probabilities according to these criteria: 
• Score of a strain unique epitope: !" ! ! ! > 1.64 → ! !, ! ! = ! ! !  
• Score of a vaccine unique epitope: !" ! ! ! > 1.64 → ! !, ! ! = ! ! ! 
Note that for any given i,j, predicted epitopes cannot be both shared and unique for allele a, but they 
can be both strain unique and vaccine unique if i and j are predicted to bind allele a, and their TCRf are 
distinct. For i,j where both 9-mers are not predicted to bind allele a, S(i,j)a and U(i,j)a are 
undetermined. 
Since the alleles in A are distinct, they are treated independently; hence, the score of shared 
epitopes for i,j over the full set of alleles can be calculated as a joint probability (i.e. product of the 
shared binding probabilities for individual alleles). However, given that the score of a shared epitope is 
calculated only for i,j where both 9-mers are predicted to be binders, the joint probability over multiple 
alleles underweights shared promiscuous epitopes. For this reason, we computed the sum of the 
probabilities instead.  
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 For the calculation of the EpiCC score, we assume that binding of each 9-mer epitope is 
mutually exclusive and uniform. Thus, E is the sum of shared and unique epitope scores of each i,j 
normalized by the total number of compared pairs p to account for variable epitope densities, and by the 
number of MHC alleles in A allowing for comparison of values of E determined using different 
numbers of MHC alleles. Formally, the EpiCC score for sequences from a vaccine and strain is 
computed as: 
!(!, !)! = 1|!| ∙ |!| !(!, !)!!∈!!∈!;!∈! − ! !, ! ! 
The sum of class I and II E(s,v)A is the total epitope-based relatedness score for s and v. Note that 
U(i,j)a functions as a penalty; therefore, if ! !, ! ! > !(!, !)!, E(s,v)A  is negative.  
 Comparison of the predicted epitope content of any sequence to itself is considered its baseline 
EpiCC score (E(s,s)A; Fig. 1) and it represents the predicted epitope density of the sequence and the 
binding probabilities of its epitopes. It follows that the maximum value of E(s,v)A can only be less than 
or equal to E(v,v)A or E(s,s)A. For vaccines with low epitope content, E(v,v)A will be low, and E(s,v)A 
will be also low, even if s and v epitopes are highly similar. Thus, low E(s,v)A can be due to low epitope 
content of one or both sequences and/or low epitope relatedness between strains. 
HA baseline EpiCC score comparison 
We calculated the baseline EpiCC score of the HA sequence of each viral strain (E(s,s)A). So as to 
evaluate whether the selection of MHC alleles had an effect on the baseline EpiCC scores, E(s,s)A was 
calculated using the epitope content predicted with four different sets of MHC alleles A (SLA-I, SLA-II, 
HLA-I, and HLA-II). 
Comparison of HA T cell epitope content between field and vaccine viruses 
We compared the epitope content (predicted using SLA alleles) of each HA to that of FS vaccine   
viruses (E(s,v)A). Shared and unique class I, class II and total EpiCC scores were determined. We also 
explored the relationships between protein identity and EpiCC scores using regressions. To represent 
the presumed lower end of the identity spectrum, we analyzed HA from A/swine/North 
Carolina/A01442548/2012 (H3N2) and A/swine/Missouri/A01727926/2015 (H4N6) viruses (GenBank 
accession KC445235 and KU641621, respectively); their HA amino acid sequences had identities 
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between 41.1% and 43.6% when compared to HA from FS viruses. A random sequence that had the 
same number of amino acids as the average HA sequence in this data set and the average amino acid 
frequencies of the proteins in the Swiss-Prot database, was also included in the comparison. 
Relationship between EpiCC scores and vaccine efficacy 
Based on reports of the experimental outcomes of previously published challenge studies and challenge 
studies performed by Zoetis evaluating the efficacy of the FS H1γ vaccine virus, we analyzed whether a 
certain level of T cell epitope relatedness of HA was associated with protection and could explain 
protection observed without cross-reactive antibodies, assuming minimal variation of T cell epitope 
content among internal proteins. FS was considered protective if it reduced the percentage of lung 
lesions and viral titers in nasal swabs (i.e. nasal shedding) and/or in lung or lung lavage. We defined a 
total EpiCC score threshold to predict protection as the lowest EpiCC score for the comparison between 
the FS H1γ vaccine virus and challenge viruses, where studies demonstrated that the vaccine was 
protective. 
Statistical analysis 
Wilcoxon matched-pairs signed rank test was used to compare baseline EpiCC score of HA sequences 
defined using different sets of MHC alleles (e.g. E(s,s)SLA-I vs. E(s,s)SLA-II; E(s,s)SLA-I vs. E(s,s)HLA-I). The 
same test was applied to evaluate differences between SLA class I and II EpiCC scores for each vaccine 
virus. Correlation between class I and II baseline EpiCC scores was determined using the nonparametric 
Spearman’s correlation coefficient (ρ). Correlation of class I and II EpiCC scores was evaluated using 
the same test. The correlation between identity and EpiCC scores was determined by Pearson 
correlation (r). P values (p) less than 0.05 were deemed significant. Analyses were performed using R 
3.3.1 (Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
HA baseline EpiCC scores, E(s,s)A 
HA sequences from a range of swine IAV phylo-clusters (Fig. 2) were analyzed. Although vaccines for 
influenza contain many antigens, the critical antigen (and the most variable) is HA. Thus, for this 
analysis, we assumed HA as the main source of T cell epitope variability among viral strains. Across 
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the 23 H1 viruses, HA SLA class I baseline EpiCC scores, E(s,s)SLA-I, were significantly lower 
(p<0.001) and less variable (0.049 (0.001); mean (standard deviation)) than class II, E(s,s)SLA-II, (0.068 
(0.004)) (Supplemental Fig. 1, SLA alleles), and they were not significantly correlated (ρ= 0.18, 
p=0.19). HA proteins from recently reported H1δ1 cluster viruses had the highest class II and total 
baseline EpiCC scores.  
 To evaluate the effect of allele specificity and the breadth of coverage of the set of SLA alleles, 
we compared the baseline EpiCC scores predicted using SLA alleles to that predicted using supertype 
HLA alleles. Class I baseline EpiCC scores for HLA alleles, E(s,s)HLA-I, (0.063 (0.002)) were 
significantly higher (p<0.001) than those predicted using SLA alleles, E(s,s)SLA-I (0.049 (0.001); 
Supplemental Fig. 1). E(s,s)HLA-II (0.065 (0.004)) were significantly lower (p<0.05) than E(s,s)SLA-II 
(0.068 (0.004)). The lower baseline scores observed for SLA class I alleles as compared to HLA class I 
alleles may indicate that the set of SLA-I alleles selected for this study was not as broad in terms of 
population coverage and might not capture all the T cell epitope differences between strains. 
Alternatively, the strains may contain fewer epitopes that bind to SLA class I alleles, which is similar to 
the significantly lower (p=0.04) HLA class I baseline EpiCC scores compared to those of HLA class II 
using supertype HLA alleles. This result suggests that it is possible that for these sets of HAs and MHC 
alleles, class I epitope content is lower than that of class II. 
Comparison of HA T cell epitope content between field and vaccine viruses 
We then compared the SLA class I and II epitope content predicted for HA of each field virus to that of 
the vaccine viruses. Intuitively, HA proteins from similar strains will have similar epitope content. We 
observed that HA sequences from viruses within the same H1 cluster or in a cluster of the same HA 
lineage (cH1N1 or human seasonal) had higher scores for class I and II shared epitopes and lower 
scores for unique epitopes than viruses in clusters from a different HA lineage (Fig. 3). It is noteworthy 
that there were shared epitopes in all comparisons, even when comparing viruses from different HA 
lineages.  
 Scores of shared, strain unique and vaccine unique SLA class II epitopes were significantly 
higher than those for class I (p<0.001 for the three vaccine viruses), with the exception of scores of H1γ 
FS vaccine unique epitopes (p=0.05). Likewise, using HLA supertype alleles, scores of class II shared 
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epitopes were also significantly higher than those for class I (p<0.01) (Supplemental Fig. 2). Class II 
scores of unique epitopes were also higher for OK08 H1δ1 FS (vaccine unique) and NC05 H1δ2 FS 
(strain unique). Although the population coverage of the set of SLA class I may be limited, the scores 
calculated using HLA supertype alleles supports that it is possible that the analyzed HA sequences had 
lower class I than class II scores. Regardless, the comparison between strains was performed using 
identical sets of SLA class I and II alleles, normalizing the comparisons. 
 Using radar plots, it is possible to visualize differences between the EpiCC scores of each 
vaccine virus compared to each field virus. In Fig. 4, each axis corresponds to one virus HA sequence. 
The HA sequences are sorted clockwise by nucleotide identity, relative to the IA00 H1γ FS virus. The 
radar plots show that nucleotide identity did not exactly correlate with EpiCC scores (e.g. IA12 H1γ-2 
and IA15 H1γ). The highest scores on each of the plots is E(v,v)A (i.e. vaccine compared to itself). HA 
sequences of viruses with the same H1 cluster of the vaccine registered the highest EpiCC scores. Note 
that for comparisons where the score for unique epitopes was greater than the score for shared epitopes, 
EpiCC scores were below zero. For each vaccine virus class I and II EpiCC scores were significantly 
different from each other (p<0.05).   
 Class I and II EpiCC scores correlated with the HA amino acid sequence identity of vaccines 
and viral strains (r=0.86 – 0.89). However, the relationship between identity and EpiCC scores was 
nonlinear second order polynomial (Fig. 5; R2=0.94 – 0.98).  EpiCC scores for sequences that had 
approximately 40% identity were no different from EpiCC scores for random amino acid sequence of 
similar length. Similar results were observed for correlation with HA nucleotide sequence identity 
(Supplemental Fig. 3). Unlike identity, EpiCC scores account only for differences in amino acids 
involved in predicted T cell epitopes. For example, there are only 35 amino acids that differ between the 
vaccine strain IA00 H1γ FS and the field strain CA09 H1pdm, but only 16 of these amino acids were 
involved in putative SLA binders and had an effect in the class II EpiCC score. Furthermore, only four 
of the residues were contained in 9-mers that were predicted to bind to three or more class II SLA 
alleles. 
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Relationship between EpiCC scores and vaccine efficacy 
We compared EpiCC scores with results of reported vaccine efficacy studies for the FS γ-cluster 
vaccine strain (IA00 H1γ FS) against heterologous viruses representing α, β, γ, or H1pdm clusters 
(Table 2) to evaluate whether certain level of HA T cell epitope relatedness between vaccine and 
challenge strains was associated with protection. The primary measure for assessing vaccine efficacy in 
these studies was reduction of lung lesions, with reduction of viral nasal shedding and/or virus titers in 
lung or lavage fluid at necropsy as secondary outcomes. A vaccine was considered protective in our 
analysis if there was a reduction of macroscopic pneumonia and virus titers in nasal swabs and/or in 
lung specimens collected at necropsy. If the vaccine significantly reduced virus titers, but not lung 
lesions, it was considered partially protective. Using these data, we found a total EpiCC score (sum of 
class I and II EpiCC scores) threshold associated with protective efficacy for this set of challenge 
studies.   
 For the six vaccine efficacy studies considered in this analysis, FS conferred protection against 
challenge with five different H1 cluster viruses (Table 2). With the exception of one study, protection 
was conferred despite low levels of HI cross-reactive antibodies (HI GMT to challenge virus ≤20). For 
these studies, the threshold associated with protective efficacy was defined as the lowest total EpiCC 
score (-0.002; MN02 H1β) comparing these five challenge strains with the vaccine strain (IA00 H1γ 
FS). This threshold defines the white area in Fig. 6. For strains with EpiCC scores above the threshold, 
the scores of shared epitopes represented at least 66.1% (0.078) of the vaccine’s baseline EpiCC score 
(0.118; Supplementary Table 1), which may suggest that a field strain or a vaccine strain (or both) may 
have many unique epitopes, but as long as there is a sufficient level of shared epitopes relative to the 
baseline, a vaccine will be protective. 
 In addition, the IA00 H1γ vaccine induced partial protection against challenge with IL08 H1α. 
This EpiCC score (-0.038) was considered a threshold associated with partial protection. This threshold 
separates the light grey from the dark grey area in Fig. 6. IL08 H1α’s shared epitopes score was 57.6% 
(0.068) of the vaccine’s baseline EpiCC score. EpiCC scores for the H1δ cluster viruses, and the IA30 
cH1 and SD15 H1α strains were below this threshold in the dark grey area.  
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 Based on the association between total EpiCC scores of HA and vaccine efficacy, we speculate 
that immunization with the IA00 H1γ FS vaccine strain could confer protection against challenge with 
viruses with scores above -0.002 (white area in Fig. 6) and partial protection for challenge-vaccine 
EpiCC scores between -0.002 and -0.038 (light gray area in Fig. 6), assuming minimal variation of 
internal antigens. In contrast, the vaccine might not protect against viruses for which EpiCC scores fall 
in the dark gray area of Fig. 6. Important differences between strain identity and EpiCC scores can be 
identified; for example, the amino acid sequence of IA12 H1γ-2 virus HA is highly identical to IA00 
H1γ FS (93.36%); however, its total EpiCC score (-0.023) is below the threshold associated with 
protection, but above the threshold for partial protection. The low total EpiCC score is driven by a low 
score for shared epitopes (0.071; 60.2%) and high score for unique epitopes (0.093; Supplemental Table 
1). Nevertheless, shared epitopes might still contribute to a certain level of protection. 
 
Discussion 
EpiCC is a method for assessing the relationship between field and vaccine strains of pathogens using 
predicted T cell epitope content as a metric for comparison. As compared to standard methods for 
estimating vaccine efficacy, such as determining whether immunization induces cross-reactive 
antibodies to the HA proteins, or measuring genetic differences by sequence similarity, EpiCC 
characterizes the differences based on portions of the virus that the immune system processes and 
presents to T cells that drive protective responses. The EpiCC calculation considers the epitope content 
shared between sequences and penalizes strain and vaccine unique epitopes. As a first test of the EpiCC 
scoring system, we compared the T cell epitope content of 20 HA sequences from different H1 clusters 
present in the North American swine population to that of three HA sequences from H1 viruses 
contained in a commercial swine IAV vaccine. To evaluate whether T cell epitope relatedness between 
vaccine and non-homologous challenge strains was associated with protection, we compared EpiCC 
scores with experimental outcomes of efficacy studies of FS H1γ vaccine virus where protection was 
induced without cross-reactive HA antibodies. The results of the analysis, performed without 
foreknowledge of efficacy outcomes, showed a threshold of T cell epitope relatedness that explained 
protection.  
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 We do not yet know whether the threshold score would apply to new strains or different 
vaccines. The thresholds described in this study were based on experimental data from only six vaccine 
efficacy studies against challenge with cH1-lineage viruses. To evaluate whether the thresholds could 
be applied to other vaccines, we compared the epitope content predicted using supertype class I and II 
HLA alleles of the HA sequence of A/Brisbane/59/2007, the H1 virus in the pre-pandemic (2008-2009) 
conventional influenza vaccine, and that of CA09 H1pdm. The total EpiCC score (-0.023) fell in the 
area of partial protection, which is consistent with the reduced influenza-like illnesses and confirmed 
infection among older adults in the absence of cross-reactive antibodies [34]. However, additional 
efficacy studies would help to refine the thresholds for prediction of protection and partial protection. 
Further studies are also required to extend these findings to other IAV strains, and to determine whether 
EpiCC scores can be used to define thresholds of vaccine efficacy for other economically important 
pathogens affecting the swine industry. 
 We note that the set of MHC alleles used for the prediction of epitopes influenced the scores of 
shared and unique epitopes, and therefore the EpiCC scores, between vaccine strains and field viruses. 
To illustrate this point, EpiCC scores calculated using binding predictions to SLA alleles were shown to 
be different from those determined using a set of supertype HLA alleles. For this study, SLA allele 
selection was based on frequencies determined using low-resolution haplotyping for a small number of 
pigs [22]. The relevance of these differences using distinct sets of MHC alleles is unknown; however, 
the distribution of SLA alleles for the North American swine population has yet to be defined, and 
therefore the EpiCC scores might be different using a more comprehensive set of alleles. Development 
of a high-throughput SLA typing system paired with a systematic study of SLA diversity would 
improve the utility of the EpiCC analysis for swine populations not only for IAV, but also for other 
economically important pathogens affecting the swine industry. Nevertheless, EpiCC scores may be 
useful for estimating vaccine efficacy for populations of swine for which SLA types are well-defined 
(e.g. for commercial pork operations where breeding practices limit SLA diversity). 
 We do not know which component of the score (shared class II epitopes or shared class I 
epitopes, for example), is more important for predicting protection. Published information describing T 
cell-dependent (CMI) responses elicited by swine IAV vaccines is scarce and some studies have 
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reported that CMI responses to inactivated vaccines can be limited in pigs [35]. However, other studies 
showed that inactivated vaccines can prime the CD4+CD8+ (double-positive) memory T cell subset 
[9,36,37]. Porcine CD4+CD8+ T cells are MHC class II-restricted memory cells that have T helper 
function [38]; and also express perforin and mediate cytolytic activity against virus-infected cells [39]. 
For the set of alleles used for epitope prediction in this analysis, we found higher scores for class II 
epitopes shared between vaccines and field virus HAs compared to those of class I. Should further 
studies determine that cross-reactive class II epitopes are more relevant for vaccine protection, a 
weighted EpiCC score that favors class II epitopes could be applied. Furthermore, alternative versions 
of the calculation (with or without scores of unique T cell epitopes) were tested. Future studies using 
more vaccine efficacy data will consider all these versions to determine predictive advantage of one 
calculation over the others.  
 EpiCC scores showing high levels of T cell epitope relatedness could explain how protection 
against challenge can be observed in an absence of HI cross-reactivity in experimental efficacy studies 
of the FS γ-cluster vaccine virus. The IA00 H1γ FS vaccine virus was genetically and antigenically 
distinct from the challenge viruses used in the six experimental challenge studies for which efficacy 
data were available. However, under the conditions of these experimental studies, vaccination provided 
protection or partial protection against MN11 H1γ, IA92 H1α, OH10 H1γ, and CA09 H1pdm with HI 
titers lower than 1:40 (the cutoff generally considered predictive of protection) [6,9–11]. Accordingly, 
MN11 H1γ, IA92 H1α, and OH10 H1γ had the highest EpiCC scores among evaluated HA sequences 
when compared to IA00 H1γ FS; CA09 H1pdm had the sixth highest score. Among these viruses, only 
IA92 H1α and CA09 H1pdm have different internal genes [3]. IA92 H1α predates the emergence of 
TRIG, and CA09 H1pdm was classified as a swine-origin IAV because internal and HA gene segments 
were genetically similar to those in the triple-reassortant viruses circulating in North American swine 
[40]. Some differences in strain-specific T cell epitope content of internal proteins should be expected. 
Notwithstanding these potential differences, the IA00 H1γ FS vaccine was protective against challenge 
with both strains [6,9]. This result may suggest that a certain level of shared T cell epitopes could be 
associated with protection, despite the presence of unique epitopes. Antibodies to other surface antigens 
may have also played a role in protection. 
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 This analysis was limited to T cell epitopes predicted from the sequences of the highly variable 
external IAV protein, HA. The specific role of HA T cell epitopes in protection against influenza in pigs 
is not yet known; however, human studies showed that vaccination with a monovalent subunit CA09 
H1pdm vaccine elicited robust HA-specific CD4 T cell responses dominated by memory CD4 T cells 
specific for peptides shared between the seasonal and pandemic strain. Researchers also demonstrated 
that expansion of CD4 T cells specific for peptide epitopes within HA, but not NP, correlated with 
neutralizing antibody response [41,42]. These results support the notion that a greater degree of CD4 T 
cell cross-reactivity may be responsible for the better antibody response.  
 CMI responses directed to the conserved internal proteins of influenza viruses are highly cross-
reactive [43,44]. In pigs, two evolutionary lineages (H1pdm09 and TRIG) dominate the selection of 
internal genes in the circulating influenza viruses, leading to a high degree of conservation in the 
internal genes [3,23,24]. As a result, much of the antigenic variability between IAV strains circulating 
in swine is determined by variable surface antigens (HA, NA and M2). We previously identified SLA-
restricted epitopes derived from HA, NA and M conserved in IAV from different HA subtypes [22]. 
Other groups have reported SLA class I-restricted epitopes in HA and NA [45,46]. Future studies will 
compare the utility of including other surface antigens (such as NA and M2) in the EpiCC score to 
determine whether thresholds revealed by HA-specific T cell epitope relatedness can be further refined. 
 Genetic sequence comparison of HA is also used for predicting potential cross-protective 
efficacy of vaccines. The relationship between EpiCC scores and HA amino acid sequence identity was 
nonlinear. At approximately 40% identity, epitope-based relatedness was similar to the EpiCC score of 
a random amino acid sequence of the same length. And while changes in amino acids affecting T cell 
epitopes can have a significant impact on the immunogenicity of an antigen [47,48], their effect on 
whole antigen sequence similarity may be minimal. To illustrate this point, we found viruses that had 
low EpiCC scores despite having high sequence identity. For example, when IA00 H1γ FS is compared 
to IA12 H1γ-2 the EpiCC score is above the threshold set for partial protection, but below the threshold 
for protection. Although H1γ-2 cluster viruses were infrequently detected in the U.S. swine population, 
characterization of H1γ-2 viruses demonstrated divergent antigenic properties with viruses within the 
same clade and viruses from contemporary swine H1 clusters as well as commercial vaccines, 
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suggesting a potential risk of vaccine failure against H1γ-2 viruses [3]. On the contrary, EpiCC analysis 
suggests that the H1γ cluster vaccine virus may induce at least partial protection against IA12 H1γ-2 
virus.  
 In conclusion, we developed the EpiCC algorithm to assess the immunologic relatedness 
between antigens based on their predicted T cell epitope content. Using EpiCC, we found that vaccine 
protection conferred by the FS IA00 H1 γ-cluster, in the absence of HI cross-reactive antibodies, might 
be explained by predicted T cell epitope content relatedness between challenge and vaccine viruses. 
Based on these results, we proposed EpiCC score thresholds for prediction of full and partial protection. 
EpiCC scores were dependent on a set of swine MHC alleles used for the predictions of epitopes; thus 
future EpiCC scores for these sequences may differ from the scores reported here. As information about 
SLA prevalence in North American swine populations becomes available, the impact of MHC allele 
selection on EpiCC scores will be assessed further. Despite these limitations, this study provides 
preliminary evidence that EpiCC may be of use as an additional measure for selecting the best-matched 
vaccine virus for immunization against IAV in a herd, and possibly to help predict whether current 
vaccines would protect against novel viruses introduced into the swine population. Additional data from 
vaccine efficacy studies will be useful to validate and optimize these thresholds. 
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Table 1. HA sequence information for swine H1 IAV.  
Virus namea Virus H1 cluster Label
b 
GenBank 
accession or 
sourcec 
A/swine/Iowa/15/1930 (H1N1) classical IA30 cH1 EU139823 
A/swine/Illinois/02450/2008 (H1N1) α IL08 H1α CY099052 
A/swine/South Dakota/A01823598/2015 
(H1N2) 
α SD15 H1α KT356682 
A/swine/St-Hyacinthe/106/1991 (H1N1) α SH91 H1α U11857 
A/swine/Iowa/40766/1992 (H1N1) α IA92 H1α KP788773 
A/swine/Minnesota/00040/2002 (H1N1) β MN02 H1β Zoetis 
A/swine/Iowa/00239/2004 (H1N1) β IA04 H1β KM198690 
A/swine/Iowa/110600/2000 (H1N1) γ IA00 H1γ FS Zoetis 
A/swine/Minnesota/PAH618/2011 (H1N1) γ MN11 H1γ Zoetis 
A/swine/Ohio/02973/2010 (H1N1) γ OH10 H1γ Zoetis 
A/swine/Iowa/A01940123/2015 (H1N1) γ IA15 H1γ KT699044 
A/swine/Minnesota/A01940015/2015 (H1N1) γ MN15 H1γ KT595733 
A/swine/Iowa/A01410129/2012 (H1N1) γ2 IA12 H1γ-2 KJ397936 
A/California/04/2009 (H1N1) H1N1pdm09 CA09 H1pdm GQ117044 
A/swine/Oklahoma/0726H/2008 (H1N2) δ1 OK08 H1δ1 FS Zoetis 
A/swine/Ontario/55383/04 (H1N2) δ1 ON04 H1δ1 DQ280212 
A/swine/Illinois/PAH710/2011 (H1N2) δ1 IL11 H1δ1 Zoetis 
A/swine/South Dakota/A01823304/2015 
(H1N2) 
δ1 SD15 H1δ1 KT277819 
A/swine/Oklahoma/A01566774/2014 (H1N2) δ1 OK14 H1δ1 KP270784 
A/swine/Minnesota/A01823864/2015 (H1N2) δ1 MN15a H1δ1 KT699050 
A/swine/Iowa/A01823426/2015 (H1N2) δ1 IA15 H1δ1 KT356694 
A/swine/Minnesota/A01940042/2015 (H1N2) δ1 MN15b H1δ1 KT733589 
A/swine/North Carolina/031/2005 (H1N1) δ2 NC05 H1δ2 FS Zoetis 
A/swine/NC/00573/2005 (H1N1) δ2 NC05 H1δ2 FJ638306 
aFS viruses are shown in bold font. 
bFS viruses have 'FS' at the end of their labels.  
cSequences marked ‘Zoetis’ were provided by Zoetis and are considered proprietary. 
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Table 2. FluSure XP® vaccination and challenge studies. 
Heterologous 
challenge Measurement of protection
a 
HI GMT to 
challenge 
virus 
Outcome Ref. 
Virus 
Percentage of 
macroscopic 
pneumonia 
Virus titers in 
nasal swabs 
Virus titers in 
lungs 
MN02 H1β Reduced Reduced Not available 80 Protection 7 
IA92 H1α Significantly 
reduced 
Significantly 
reduced 
Not available ≤20 Protection 9 
CA09 H1pdm Significantly 
reduced 
Significantly 
reduced 
Significantly 
reduced 
≤10 Protection 6 
OH10 H1γ Significantly 
reduced 
Not available Significantly 
reduced 
≤10 Protection 10 
MN11 H1γ Significantly 
reduced 
Significantly 
reduced 
Significantly 
reduced 
≤20 Protection 11 
IL08 H1α Not significantly 
different 
Significantly 
reduced 
Significantly 
reduced 
≤20 Partial 
protection 
12 
aSignificance of outcomes was as measured and reported in the original references. 
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Fig. 1. Illustration of T cell epitope content comparison (EpiCC) score calculation. Strain A and 
Vaccine were screened for binding likelihood to a set of four MHC alleles; 9-mers (rows) predicted to 
bind to specific MHC alleles (columns) are shown in light (top 5%) or dark (top 1%) blue. The 
comparison of the epitope content of Strain A to itself determines the baseline EpiCC score (left). For 
the comparison between Strain A and Vaccine, scores of shared and unique epitopes are considered 
when calculating the EpiCC score (right). 
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Fig.	 2. Phylogenetic tree for the HA nucleotide sequences of IAV field and vaccine viruses 
representing H1 phylo-cluster in the North American swine. Bootstrap test results are shown next to 
the branches. 
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Fig.	 3. Comparison of scores of shared and unique epitopes across strains. Scores of shared, 
vaccine unique and strain unique SLA class I and II epitopes were determined for the comparison of 
HA sequences from vaccine viruses and field (challenge) strains. Note that y-axes show different scales. 
Solid connecting lines are included only for visualization purposes. P-values of comparisons were 
calculated using one-tailed Wilcoxon matched-pairs signed rank test (**p<0.001). HA vaccine 
sequences had higher scores for shared epitopes with strains belonging to the same H1 cluster or the 
same HA lineage. In general, scores of class II shared and unique epitopes were significantly higher 
than those of class I. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the 
x-axis are described in detail in the legend below. 
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Fig. 4. EpiCC score comparisons between HA sequences of FS vaccine viruses and field viruses. 
Each axis corresponds to the HA sequence of one virus. EpiCC score = Scores of shared epitopes - 
Scores of strain and vaccine unique epitopes. 
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Fig. 5. Relationship between EpiCC scores and identity. The second order polynomial relationship 
between class I (top), II (bottom) EpiCC scores, and amino acid identity for each FS virus are shown. 
R2 of regression models are shown. H3N2, H4N6 and a random sequence were included in this analysis 
to represent the lower end of the identity range. Interestingly, there were instances where viruses had 
low EpiCC scores despite high identity (e.g. class II epitope content of IA00 H1γ FS compared to SD15 
H1α). 
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Fig. 6. Definition of threshold for prediction of vaccine efficacy prediction. Total EpiCC scores 
(blue line) for the comparison of H1γ FS and each viral strain are shown. The FS γ-cluster vaccine 
strain was protective or partially protective against challenge with viruses annotated as (P) or (PP), 
respectively. The rest of the viruses were not tested as challenge strains. Protection and partial 
protection thresholds (black lines) defined three areas shown in white (protection; total EpiCC score 
above -0.002), light gray (partial protection) and dark gray (no protection). Viruses used to set the 
thresholds are marked with an asterisk (*). We hypothesize that FS would confer at least partial 
protection against challenge with viruses that had EpiCC scores outside the darker gray region. 
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CHAPTER 5 
Conclusions 
The development of immunoinformatics tools has had a significant impact on human 
immunology research, discovery of immunogenic epitopes and design of vaccines for diverse 
pathogens. One of the main applications of immunoinformatics is T cell epitope prediction due to their 
critical role in cell-mediated immunity (CMI). T cell epitope mapping algorithms can easily analyze 
complete proteomes of any size to identify candidates for further experimental validation. However, 
immunoinformatics tools are very limited for non-human species. In this thesis, concepts and 
information used to construct immunoinformatics methods for humans were applied to develop novel T 
cell epitope-based immunoinformatics tools for swine.  
PigMatrix has been designed to map swine T cell epitopes using the pocket profile method. 
This method was applied to overcome the lack of SLA-specific binding data required to train and test 
predictors by leveraging predefined binding preferences for HLA. The pocket profile method has been 
previously applied for prediction of binding to HLA alleles with limited binding data [1,2]. This is the 
first formal application and evaluation of the method for a non-human species. Different approaches 
were tested to define pocket residues (based on SLA or HLA structures) and similarity between SLA 
and HLA pockets for selection of the best human match. Without any training step, PigMatrix achieved 
a favorable predictive performance, comparable to or better than other available methods for SLA class 
I alleles. It is noteworthy that PigMatrix is the first tool designed for prediction of SLA class II T cell 
epitopes.  
The current implementation of PigMatrix compares the sequences of an SLA pocket to a 
library of HLA pockets and calculates a similarity score to identify the best human match and infer 
binding preferences. The library of HLA pockets is comprised of HLA supertype alleles, but it can be 
readily extended to include more alleles with defined binding specificities. Thus, it would be possible to 
find better human matches, which may improve PigMatrix predictions. Furthermore, weighting the 
similarity score by conservation of key contact residues or biochemical properties in the pocket may 
also improve the selection of the best human match.  
Larger datasets of SLA-restricted peptides are required to further evaluate the PigMatrix 
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approach and improve the predictions. To generate quantitative binding data and test PigMatrix, binding 
assays for commonly expressed SLA molecules could be developed. These assays would provide 
valuable information to better define binding preferences and potentially develop predictions based on 
SLA specificities rather than HLA pocket preferences. Currently, binding assays are limited to only 
three SLA class I alleles [3]. In addition, crystallographic structures of diverse SLA molecules would 
further expand our understanding of the SLA binding pockets and their specificities; only two crystal 
structures of SLA class I alleles are currently available [4,5]. Similar to class I predictions, class II 
predictions may improve if pocket residues are defined based on SLA crystal structures rather than 
structures of HLA molecules.  
Based on the initial encouraging results of PigMatrix, predictions were extended to SLA alleles 
reported to be prevalent in commercial pigs and applied to identify potentially immunogenic IAV 
peptides. IAV is considered one of the most important infectious disease agents affecting North 
American swine [6,7]. The majority of currently licensed swine IAV vaccines consist of whole 
inactivated viruses administered with adjuvant by intramuscular injection [8]. This platform primarily 
induces systemic IgG antibody responses to the surface glycoproteins, mainly HA [8,9]. However, 
antibody-mediated immunity does not typically provide protection against divergent strains of IAV 
[9,10]. Conversely, CMI can be broadly cross-reactive to a variety of IAV subtypes [11–15]. Moreover, 
CMI contributes to clearance of virus and reduced symptom severity and virus shedding [16,17]. A 
vaccine that induces CMI and reduces morbidity could prevent anorexia and weight loss, which cause 
significant economic impact to pork producers. Therefore, identification T cell epitopes conserved in 
diverse IAV represents the first step toward the development of a potentially broadly protective vaccine. 
So, PigMatrix was used to screen complete proteomes of representative IAV strains in U.S. swine for 
class I and II T cell epitopes. A prototype epitope-based DNA vaccine encoding strings of class I and II 
epitopes was developed to evaluate immunogenic responses to the putative epitopes. Eleven T cell 
epitopes induced specific IFNγ recall responses in pigs vaccinated with the prototype vaccine. Recall 
responses to peptides were not observed in pigs immunized with the inactivated commercial vaccine, 
despite containing similar internal antigens. This result shows that the epitope-based vaccine promoted 
more efficient processing and presentation of its own epitopes as compared to whole-protein-based 
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vaccines. 
In this immunogenicity study, SLA-typing performed at the end of the study revealed that the 
SLA alleles used for the prediction were not prevalent in the study cohort, which highlights that the lack 
of information on SLA frequencies in the U.S. population represents a challenge for the development of 
T cell epitope predictors for swine. Cohort-specific predictions developed to re-evaluate the putative 
epitopes showed lower binding likelihood for 46 out of 48 epitopes and were particularly effective 
identifying non-immunogenic peptides. PigMatrix might be applied to identify T cell epitopes from 
other swine pathogens, which could significantly speed the development of novel vaccines for 
infectious diseases in pigs.  
Further studies would apply PigMatrix using a more comprehensive set of SLA alleles to 
identify and add peptides to the set of highly conserved and immunogenic IAV sequences to be 
included in an epitope-driven vaccine. In addition to SLA binding assays and standard recall assays 
using blood from naturally infected or vaccinated pigs, the selection process of peptides can be 
optimized by implementing T cell assays currently applied to evaluate peptide immunogenicity for 
human studies using naive PBMCs [18]. In this protocol, before performing ELISpot assays, PBMCs 
are cultured with individual peptides over 8 days to expand peptide-specific T cells ex vivo. Results of 
this method, in a preliminary evaluation using naïve blood from pigs, showed that it is possible to 
measure specific IFNγ recall responses upon restimulation with peptides (unpublished). 
The prototype vaccine tested, developed as a tool to measure peptide immunogenicity, was 
designed to target the putative class I and class II epitopes to the endogenous and exogenous antigen 
presentation pathways, respectively. In this study, pigs were vaccinated three times intramuscularly, but 
future vaccine efficacy studies could test other immunization methods like gene gun or electroporation. 
These methods could enhance the in vivo transfection (i.e. introduction of nucleic acids into eukaryotic 
cells) efficiency of the DNA vaccine [19]. To date, three DNA vaccines have been licensed for 
veterinary use (West Nile Virus vaccine for horses [20], infectious hematopoietic necrosis virus vaccine 
for salmon [21], and a canine melanoma vaccine [22]). Moreover, the first licensed electroporation-
delivered product and first licensed gene therapy was the growth hormone-releasing hormone for use in 
swine [23]. The development of these products illustrates the advancements in DNA plasmid 
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technology and its application for animals both big and small. Other methods could be also evaluated to 
deliver immunogenic T cell epitopes. For example, alphavirus-like replicon particle (RP) technology 
has recently been approved by the USDA as a vaccine for swine IAV. This vaccine uses RP to deliver a 
sequence that encodes an H3 HA [8]. RP can be engineered to deliver peptides and an HA component 
to potentially induce both CMI and humoral responses.  
Information about SLA allele diversity in the U.S. swine population is critically important to 
develop a more comprehensive set of predictions that target the most prevalent SLA alleles. A 
commercially available high-throughput method for high-resolution SLA-typing would improve the 
ability of researchers and producers to determine SLA diversity. Researchers in other countries have 
recognized the importance of SLA diversity for vaccine development and studies to identify commonly 
expressed haplotypes have been conducted [24]. Once the prevalence and diversity of U.S. swine SLA 
are better understood, it may be possible to cluster SLA molecules into supertypes. The concept of 
supertypes has been applied to HLA for selection of few representative alleles from different clusters to 
cover a high percentage of the HLA diversity in human population [25,26]. An epitope-based vaccine 
based on peptides predicted to bind SLA supertype alleles could induce immune responses in pigs 
expressing diverse alleles. 
A novel tool for epitope content comparison called EpiCC was developed leveraging 
PigMatrix predictions. This method estimates the relationship between variable viruses based on their 
putative T cell epitope content to predict cross-protection. For influenza and other viruses, sequence 
data and antibody cross-reactivity are commonly used to predict vaccine-induced protection. However, 
previous efficacy studies demonstrated that in the absence of cross-reactive antibodies, a commercial 
swine IAV vaccine was capable of inducing protection or partial protection against heterologous 
challenge strains [9,27–31]. The EpiCC analysis showed that T cell epitope-based relatedness between 
HA proteins of the vaccine and challenge strains was associated with vaccine-induced protection. The 
results also demonstrated that the T cell epitope content depends on the set of MHC alleles used for the 
predictions of epitopes. EpiCC analysis may complement current methods for vaccine selection in 
outbreak situations and strain selection for vaccine production. 
Future studies of EpiCC could explore different criteria to define shared and unique epitopes. 
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The current definition of shared (or cross-reactive) and unique epitopes is very stringent (only epitopes 
predicted to bind to the same SLA allele with identical TCR-facing residues were considered cross-
reactive); it is likely that this approach underestimates the full set of shared epitopes between vaccines 
and viruses, but it provides a reasonably conservative means to determine the minimum shared T cell 
epitope content. In reality, epitope cross-reactivity is conformational, hence, it is possible that epitopes 
with different TCR-facing residues and completely different sequences can be recognized by the same 
TCR [32,33]. EpiCC will be tested applying less restrictive criteria for cross-reactivity allowing for 
conservative mismatches between TCR-facing residues or applying a threshold of similarity [34]. In 
addition, the initial model assumed equal importance for vaccine and strain unique epitopes as well as 
for class I and II T cell epitopes; further EpiCC analyses will evaluate the impact of incorporating 
weighted scores. 
The EpiCC analysis was restricted to HA sequences from 23 viruses representing diverse 
clusters of field strains; we assumed limited T cell epitope variation of other antigens. However, the 
same approach can be applied to multiple antigens or to complete proteomes of influenza strains or 
other pathogens. Future studies of large-scale surveillance data will be performed to identify circulating 
or novel viruses distantly related to current vaccines for further experimental evaluation to determine 
potential risk of vaccine failure. It would also be possible to identify viruses with low T cell epitope 
relatedness with vaccine viruses despite high sequence similarity (or vice versa); challenge studies with 
these viruses will provide evidence of the role of T cell epitopes in protection. Predicted T cell epitopes 
will be synthesized and tested individually using PBMCs from vaccinated pigs pre- and post-challenge 
to evaluate PigMatrix predictions as well as responses to shared and unique epitopes. In addition, more 
sophisticated methods will be explored to visualize the T cell epitope content and the epitope-based 
relationship among large number of viruses. For example, in preliminary studies, we have tested 
multidimensional scaling and distance trees to represent T cell epitope-based distances (unpublished). 
Moreover, EpiCC analysis has obvious applications to human vaccine studies, where epitope content 
could be compared for predictions using HLA alleles. 
The preliminary success of PigMatrix and EpiCC opens the door for the development of other 
immunoinformatics tools to study the immunogenicity of swine pathogens and to identify potential 
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regulatory T cell epitopes. Previous large computational studies comparing predicted human T cell 
epitopes have demonstrated differentiable patterns of TCR cross-reactivity with self, associated with 
different T cell phenotypes [35,36]. JanusMatrix is the tool developed to perform this analysis; it uses 
EpiMatrix for prediction of human T cell epitopes and then compares their TCR-facing residues against 
T cell epitopes predicted within the human proteome, human pathogens, and human microbiome to 
identify epitopes with identical TCR-facing residues [35]. JanusMatrix has shown that regulatory T cell 
epitopes have greater TCR cross-reactivity with human proteins than effector T cell epitopes [35]. 
Integrating both MHC binding and TCR cross-reactivity to self, the Janus Immunogenicity Score has 
been developed to predict viral and bacterial immunogenicity potential [36,37]. These analyses have 
provided evidence of a pathogen mechanism of ‘immune camouflage’ to avoid immune recognition by 
reducing the MHC and/or TCR binding of their peptides. We are now in the unique position to extend 
these approaches to swine. Prediction of potential regulatory T cell epitopes may have a significant 
impact in swine vaccine design. For example, porcine reproductive and respiratory syndrome virus 
(PRRSV) causes one of the most devastating swine diseases worldwide. One of the mechanisms 
associated with the ability of PRRSV to negatively modulate the host immune system is the induction 
of regulatory T cells [38]. A version of JanusMatrix equipped to predict swine T cell epitopes could 
help to find potential regulatory T cell PRRSV epitopes for experimental evaluation. Thus, PigMatrix 
and JanusMatrix could help to better classify pathogen epitopes, which will improve future vaccine 
designs.   
Animal researchers are starting to recognize the value and diverse applications of 
immunoinformatics in the veterinary field. The development of predictive tools for swine T cell 
epitopes, their application to the analysis of existing vaccines, and the design of new vaccine 
prototypes, demonstrates the potential of immunoinformatics to aid and accelerate swine vaccine 
development and paves the way for future advancements for other important livestock species. 
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APPENDICES 
Supplemental information for Chapter 2 
Supplemental Table 1. Peptide database. 
Exp: Experimental results; 0: Non-binders, 1: Binder 
SLA-1*0401 SLA-2*0401 SLA-3*0401 SLA-DRB1*0201 
Sequence Exp Sequence Exp Sequence Exp Sequence Exp 
ALTDLGLIY 1 AAKHMSNTY 0 AMYDPQTYY 0 AAAPSTTTALDTTPN 0 
AMYDPQTYY 1 ASYQFQLPY 1 ASYAAAAAY 0 AAFVTNSTVADELGR 0 
ASAAHLAAY 1 ATAAATEAY 1 FLYPSWSLY 0 ADALAPVVVEGERAT 0 
ASFAAQLFY 0 ATAVNQECW 0 FQMDYSLEY 0 ADPEYFDEPPRPELP 0 
ASYAAAAAY 1 DTRAIDQFF 0 GMFANRWII 0 AEWILKTLVNTEHAY 0 
ASYAGAGAY 1 ESLLHQASW 1 GMFSWNLAY 0 AFLICLIKVLRGQIV 1 
ASYGAGAGY 1 ESPSSDEDY 0 HMMAVTLFY 0 AHGRKRIVCRERLFS 0 
ASYQFQLPY 1 FAHDDRYLY 0 HQYPANLFY 0 AHGVFNPEFGPAALS 0 
ATAAATEAY 1 FGMPNPEGY 0 ITMVNSLTY 0 ALKLMEKREYKFTCQ 0 
ATAWRTGGY 1 FQMDYSLEY 0 KARARLLSM 1 ALLALYAAAIAAAPS 0 
ATDFKFAMY 1 FSSQLGLFY 0 KMFHGGLRY 0 ANHCSDAMNIMFEEV 0 
ATEDPSSGY 1 FSVPLDEGF 0 KNNFWFWEY 1 APASPEAGAVSTPPV 0 
ATIMPHNLY 0 FTFWTFANY 1 KRIRLKHIF 1 APGLPWALQGKRRGA 0 
ATTFARFLY 1 FTIRDVLAY 1 KRMMMNLNY 1 AQMHSNNGPQIGSAV 0 
ATVKGMQSY 1 HMMAVTLFY 0 KSFFSRLNW 1 AQYRNVWDVDYSAFD 0 
ATYQRTRAL 0 HQYPANLFY 0 KSYEHQTPF 1 ARAMLALLALYAAAI 0 
AVDVDDGHF 1 HSNLNDATY 0 KTLKGGWFF 1 ASLAHADALAPVVVE 0 
AVEDFLAFF 1 HTAEIQQFF 0 LNIMNKLNI 1 ATLSKNKNCILCTVC 1 
AVEGGLYPV 1 HTSALSLGY 1 LNWFEIWIV 0 AVHSGPDEYRRLFEP 0 
AVSFRNLAY 1 IIYYQLAGY 1 LSNFMLWQF 0 AVSFGCAVFPRAGET 0 
CSDETTLYY 1 ISRQIHWCW 0 MARWITWAM 1 CAVFPRAGETFEVRF 0 
CTDDNALAY 1 ISVQPLWEW 0 MMHASTSPF 0 CDGLCVPPEARLAWS 0 
CTELKLSDY 1 ITLKVFAGY 1 MQYLNPPPY 0 CRYDKDADINVVTQA 1 
CTLNKSHLY 0 KSAAIDGEY 0 RARKRGITM 1 DAADALAPSLRCEAV 0 
DSDDWLNKY 0 KSLDNYQEW 0 RAYRNALSM 1 DAETEGVYTWRVLSA 0 
DTEDNVPPW 1 KSWPAAIDW 0 RIRAANLPI 1 DAMNIMFEEVFNTDF 0 
EIAQHGAWY 1 MANIFRGSY 0 RIYSHIAPY 0 DGLDAMEPDTAPGLP 0 
EISGSSARY 1 MLYPRVWPY 0 RLASYGLYY 0 DHAADTVYHLGACAE 0 
ESDMEVFDY 1 MNYAAAAAY 1 RLFFIDWEY 0 DKGFVLGHSITDVTF 0 
ESENISEPY 0 MTAASYARY 1 RLRRRRHPL 0 DTTPNGGGGGNSSEG 0 
ESSDDELPY 0 MTAHITVPY 1 RLYPFGSYY 0 DYRYAISSTNEIGLL 1 
ETESVNSNY 1 MTRGLLGSY 1 RMFKRVFNM 1 DYTCRLEGLPSQLPV 0 
EVAGAGSGF 1 MTRVTNNVY 0 RMFLAMITY 0 DYYPRRSVRLRWFAD 0 
EVDQTKIQY 1 MVASQLARY 1 RNMSRIFPY 1 EAGAVSTPPVPPPSV 0 
FLYPSWSLY 1 MVFQNYALY 1 RNNDPTLPY 0 EALKPHFKSLGQTIT 0 
FSIPVTFSY 0 MYADDTAGW 0 RQHPGLFPF 0 EAMTNYAKEGIQFMK 1 
FTAMQALDY 1 QQYHRFGLY 1 RRARYWLTY 1 EGFAVCDGLCVPPEA 1 
FTDNNELEF 1 QTWHGDAPY 0 RRFFPYYVY 1 EHPVDAAFVTNSTVA 0 
FTFWTFANY 1 QTYMYTGQY 0 RRFKYLLNV 1 EIRPMEKVRAGKTRI 0 
FTIRDVLAY 1 RSVWIPGRW 1 RRFNRTKPM 0 EKREYKFTCQTFLKD 0 
FTYAPAGMY 1 RVYNNTARY 0 RRLHRLLLM 1 EKVRAGKTRIVDVLP 0 
GSDGGLDDY 1 RVYPNPEVY 0 RRMATTFTF 1 ELSPSPPPTPAPASP 0 
GSQYVSLAY 0 RYQAQQVEW 0 RRRQWASCM 1 ENALLVALFGYVGYQ 1 
GTDSGFAAY 1 SAYYLDIGF 0 RRSRRSLTV 1 ENKRITVEGGMPSGC 0 
GTDSNGMLW 1 SLRPNDIVY 0 RRVRRRVLV 0 EPFRAVCVVRDYYPR 0 
GTEKLTITY 1 SSLPSYAAY 1 RSFRIHILF 0 EPIQLAYNSYETQVP 1 
GTEYRLTLY 0 SSMNSDAAY 0 RTFDRFFEE 0 ERLFSARVGDAVSFG 0 
GTFDLGGLY 0 SSNAKNSEW 0 RTLDTLALY 0 ERVHVMRKTKLAPTV 0 
GTTEVNGLY 0 SSNPVMSRF 0 RVFKETLFL 0 FDEPPRPELPRERLL 0 
GVEPGHAFY 1 SSVGVTHGY 1 RVFNNYMPY 1 FEDTQRYDASPASVS 0 
HIASMRRNY 1 SSVSSFERF 0 RVFYFAIFY 0 FEVRFYRRGRFRSPD 0 
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HMMAVTLFY 0 STEPPMLNY 0 RVRRLNWAA 1 FGTHFAQYRNVWDVD 0 
HSDDALFIY 1 STFATVLEY 0 RVYPNPEVY 0 FNTDFGFHPNAEWIL 0 
HTAAPWGSY 0 TVYNGTSKY 0 RWFVRNPFF 0 FQGLFEIPSYRSLYL 0 
HTSALSLGY 1 VSIPVTNTW 1 RYFTVAFLF 0 FRSPDADPEYFDEPP 0 
IAGFIEGGW 0 VSRLEHQMW 0 SARRRHLVF 1 FSEALRPHVYHPAAV 0 
ISAYTHWYY 1 VSYAAAAAY 1 SMFDSWGPF 0 FSSANASLAHADALA 0 
ITAGYNRYY 0 VTEPGTAQY 0 SQYHRFPIY 0 GACAEHPGLLNVRSA 0 
ITDITKYLY 1 YANMWSLMY 0 SRWSRKMLM 0 GCNPDVDWQRFGTHF 0 
ITDITSPLW 1 YAQMWSLMY 0 SSMNSFLLY 0 GDKATAHGRKRIVCR 0 
ITDYIVGYY 1 YAYNSSLLY 0 TSFASSWIY 1 GERATVANVSGEVSV 0 
ITFQSILGY 0 YLSGIAQYY 1 TTRHRKPTY 0 GEVSVRVAAADAETE 0 
ITTFFTFAY 0 YSRMLYIEF 0 TVFYNIPPM 0 GFHPNAEWILKTLVN 0 
IVDCLTEMY 1 YSYIFLSSY 0 VMFRNASEY 0 GGGGGNSSEGELSPS 0 
IVDINVKDY 1 YTASVVAAY 1 VSYAAAAAY 0 GKTRIVDVLPVEHIL 0 
KIAPLMVAY 1 YTGPDHQEW 0 VTFWGFWLF 0 GLAAADAADALAPSL 0 
KLDAWLLPF 1 YTIGIGAFY 1 YAYNSSLLY 0 GLIVDTRDVEERVHV 0 
KLDPTNTLW 1 YTITYHDDW 0 YMIGYTAYY 0 GLSAPPVLFGEPFRA 0 
KMARLGKGY 1 YTNPQFNVY 0 YRFRFRSVY 1 GLSTAENALLVALFG 1 
KMFHGGLRY 1 YTSDYFISY 1 YSRPWNWTF 1 GQTITPADKSDKGFV 0 
KSDGTGTIY 1 
  
YSYIFLSSY 0 GVYTWRVLSANGTEV 0 
KSDLQPPNY 1 
  
YTFFFTQYF 0 HFKSLGQTITPADKS 0 
KSNRIPFLY 1 
  
YTYATRGIY 0 HMDYGTGFYKPVMAS 0 
KSTDSESDW 0 
    
HPAAVSVRFVEGFAV 0 
KTAVVVTRY 1 
    
HPGLLNVRSARPLSD 0 
KTFEWGVFY 1 
    
HSVLGTANAPLSTYE 0 
KVFFGPIYY 1 
    
ICAAGSFKVTALNVV 1 
LIDGRTSFY 1 
    
IFSKHKGNTKMSEED 0 
LLDGLLAWY 1 
    
IGRFCAQMHSNNGPQ 0 
LSDDAVVCY 1 
    
IGSAVGCNPDVDWQR 0 
LSTASSWSY 1 
    
ILAIVLVIMATCVYY 0 
LTAHYCFLY 0 
    
ILSFARRGTIQEKLI 0 
LTDDMIAAY 1 
    
INTILNNIYVLYALR 0 
LTDSDSPTY 1 
    
KAILISCISNKWQFI 1 
LTFLDCLYY 0 
    
KALFRRCAADYASRL 0 
LTMDREMLY 0 
    
KFTCQTFLKDEIRPM 0 
MADSFKSDY 1 
    
KGNTKMSEEDKALFR 0 
MIDSDEWVY 1 
    
KHKVRNEVMVHWFDD 1 
MIEPRTLQY 1 
    
KKFFLLSSRVKELII 1 
MIGGIGRFY 1 
    
KKGKNFSFAGTIIEG 1 
MLASIDLKY 0 
    
KLASSAFSGLFG 1 
MSAIVSCRY 1 
    
KTLEAILSFARRGTI 1 
MSNEGSYFF 0 
    
KTLVNTEHAYENKRI 0 
MSSAAHLLY 1 
    
LAPSLRCEAVWYRDS 0 
MSWESTAEY 1 
    
LAPTVAHGVFNPEFG 0 
MTAASYARY 1 
    
LDGPVDYTCRLEGLP 0 
MTAHITVPY 1 
    
LEGLPSQLPVFEDTQ 0 
MTRGILGSY 0 
    
LGHSITDVTFLKRHF 0 
MTRGLLGSY 0 
    
LIKVLRGQIVQGVIW 1 
MTRVLPFTY 0 
    
LNEGVVLDEVIFSKH 0 
MTRVTNNVY 0 
    
LVIMATCVYYRQAGP 0 
MTSGSSSGF 1 
    
LYALRRHYEGVELDS 0 
NADTLCIGY 1 
    
MEPDTAPGLPWALQG 0 
NIDNMCHLY 1 
    
MFEEVFNTDFGFHPN 0 
NSDTVGWSW 1 
    
MMASLARAMLALLAL 0 
NTDAFSREY 1 
    
MPSGCSATSIINTIL 0 
QIGNIISIW 1 
    
MRKTKLAPTVAHGVF 0 
QSAANMYIY 0 
    
MSEEDKALFRRCAAD 0 
QTDNDIWFW 1 
    
NDWFSKLASSAF 1 
QTDNQLAVF 1 
    
NGTEVRSANVSLLLY 0 
QTDPLWQKY 1 
    
NGTVGPEVEAALKLM 0 
QTEENLLDF 1 
    
NKDPRLNEGVVLDEV 0 
QTNLYNLLY 1 
    
NNGPQIGSAVGCNPD 0 
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QTWHGDAPY 1 
    
NNIYVLYALRRHYEG 0 
QVSRPMFLY 1 
    
NPEFGPAALSNKDPR 0 
RADSMMLGY 1 
    
NSSEGELSPSPPPTP 0 
RIARFHRPY 1 
    
NSTVADELGRRTRVS 0 
RLASYGLYY 1 
    
NVRSARPLSDLDGPV 0 
RMFLAMITY 0 
    
PAALSNKDPRLNEGV 0 
RSADGSPPY 1 
    
PADKSDKGFVLGHSI 0 
RTDAWSYPV 1 
    
PASVSWPVVSSMIVV 0 
RTLASGLIY 1 
    
PDEYRRLFEPFQGLF 0 
RTWAYHGSY 1 
    
PEVEAALKLMEKREY 0 
RTWFHGSLY 1 
    
PPPSVSRRKPPRNNN 0 
RTWHYCGSY 0 
    
PPPTPAPASPEAGAV 0 
RTWNYHGSY 1 
    
PRNNNRTRVHGDKAT 0 
RVERIKSEY 1 
    
PVLFGEPFRAVCVVR 1 
RVFPGDHFY 1 
    
PVMASKTLEAILSFA 0 
RVSTGLYRY 1 
    
PVVVEGERATVANVS 0 
SSDDIPPRW 1 
    
QEKLISVAGLAVHSG 0 
SSDISFIKY 1 
    
RADVPGLAAADAADA 0 
SSDLRSWTF 1 
    
RAGETFEVRFYRRGR 0 
SSFERFEIF 0 
    
RCAADYASRLHSVLG 0 
SSMNSFLLY 1 
    
RCEAVWYRDSVASQR 0 
SSSFSFGGF 1 
    
RERLLFSSANASLAH 0 
SSVGVTHGY 1 
    
RHYEGVELDSYTMIS 0 
STAPTGSWF 1 
    
RIVCRERLFSARVGD 0 
STFATVLEY 1 
    
RLAWSDHAADTVYHL 0 
STYQPLPLY 1 
    
RLFEPFQGLFEIPSY 0 
SVAMCRTPF 1 
    
RPELPRERLLFSSAN 0 
SVDGFRASY 1 
    
RPHVYHPAAVSVRFV 0 
SVEMNAPNY 1 
    
RPLSDLDGPVDYTCR 0 
SVEVKLPDY 1 
    
RQLSSNYILELLYKF 1 
TIDKSSPLY 1 
    
RRGTIQEKLISVAGL 0 
TLELRSRYW 1 
    
RSANVSLLLYSQPEF 0 
TMDVNHPIY 1 
    
RSVRLRWFADEHPVD 0 
TQDLFLPFY 1 
    
RTRVHGDKATAHGRK 0 
TSDGFINGW 1 
    
RTRVSVVNVTRADVP 0 
TSSARSSEW 0 
    
RVAAADAETEGVYTW 0 
TTSDFFVNY 0 
    
RVLSANGTEVRSANV 0 
TVYNGTSKY 1 
    
RWFADEHPVDAAFVT 0 
VAGGTGSVY 1 
    
RYDASPASVSWPVVS 0 
VLDKWNTNY 1 
    
SATSIINTILNNIYV 0 
VSALRLFNY 0 
    
SEGKIRQLSSNYILE 1 
VSDGGPNLY 1 
    
SLLLYSQPEFGLSAP 0 
VSDGPPTGY 1 
    
SMIVVIAGIGILAIV 0 
VSFNQNLEY 0 
    
SQLPVFEDTQRYDAS 0 
VSYAAAAAY 0 
    
SQPEFGLSAPPVLFG 0 
VTDPGGLYY 1 
    
SQSPYVVVATNAIES 1 
VTIGNAYIY 0 
    
SRRKPPRNNNRTRVH 0 
VTRGAVLMY 0 
    
STPPVPPPSVSRRKP 0 
VVAANRSAF 1 
    
SVAGLAVHSGPDEYR 0 
VVDALRNIY 1 
    
SVRFVEGFAVCDGLC 1 
WSQDPTMLY 0 
    
SYFQQYMLKGEYQYW 1 
WTGMVDGWY 0 
    
TANAPLSTYEAIKGV 0 
WVAGVQLLY 0 
    
TASALYLISYYVIPQ 1 
YAQMWTLMY 1 
    
TDVTFLKRHFHMDYG 0 
YIFFASFYY 0 
    
TEHAYENKRITVEGG 0 
YLSGIAQYY 1 
    
TFLKDEIRPMEKVRA 0 
YSAEALLPY 1 
    
TGFYKPVMASKTLEA 0 
YSYIFLSSY 0 
    
TLILILPTYELTKLY 1 
YTASVVAAY 1 
    
TRDVEERVHVMRKTK 0 
YTDKIAMSY 1 
    
TRVWNSASTTAFLIC 1 
YTFEPHYFY 0 
    
TTLLNGSAFYLVCPI 1 
YTSDYFISY 1 
    
TTTALDTTPNGGGGG 0 
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YTYPCIPEY 1 
    
TVEGGMPSGCSATSI 0 
YVFVGSSRY 0 
    
TVYHLGACAEHPGLL 0 
YVFVGTSRY 1 
    
VALFGYVGYQALSKR 1 
YVYFYDLSY 1 
    
VANVSGEVSVRVAAA 0 
      
VASQRFSEALRPHVY 0 
      
VCVVRDYYPRRSVRL 0 
      
VDVLPVEHILYTRMM 0 
      
VDWQRFGTHFAQYRN 0 
      
VEHILYTRMMIGRFC 0 
      
VELDSYTMISYGDDI 0 
      
VELYYKGTTIKLDFN 1 
      
VLDEVIFSKHKGNTK 0 
      
VPPEARLAWSDHAAD 0 
      
VVASDYDLDFEALKP 0 
      
VVCQSNNKMTDESEY 1 
      
VVNVTRADVPGLAAA 0 
      
VWDVDYSAFDANHCS 0 
      
WALQGKRRGALIDFE 0 
      
WPVVSSMIVVIAGIG 0 
      
WYRDSVASQRFSEAL 0 
      
YAAAIAAAPSTTTAL 0 
      
YASRLHSVLGTANAP 0 
      
YDLDFEALKPHFKSL 1 
      
YEPRDSYFQQYMLKG 1 
      
YGDDIVVASDYDLDF 0 
      
YRRGRFRSPDADPEY 0 
      
YSAFDANHCSDAMNI 0 
      
YTMISYGDDIVVASD 0 
      
YTRMMIGRFCAQMHS 0 
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Supplemental Table 2. HLA crystal structures. 
Allele PDB 
HLA-A*0101 4NQV 
HLA-A*0201 3MRE 
HLA-A*0201 3MRG 
HLA-A*0301 3RL1 
HLA-A*1101 1X7Q 
HLA-A*2402 1P7Q 
HLA-A*6801 4HWZ 
HLA-B*0702 4U1H 
HLA-B*0801 4QRS 
HLA-B*2705 2A83 
HLA-B*3501 2CIK 
HLA-B*4403 1N2R 
HLA-B*5101 1E27 
HLA-DRB1*0101 1T5W 
HLA-DRB1*0301 1A6A 
HLA-DRB1*0401 1J8H 
HLA-DRB1*1501 1YYM 
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Supplemental Table 3. Contact residues in the SLA class II binding pockets based on HLA 
contacts (Hc). 
 
SLA Pocket (peptide position) 
position A(1) B(4) C(6) D(7) E(9) 
9H 
 
   
  
11L 
  
  
 
  
13F 
 
    
 
  
26L 
 
  
  
  
28E 
 
        
30Q 
  
      
37F 
    
  
38L 
    
  
47Y 
   
   
57D 
    
  
60D 
    
  
61W 
   
   
67L 
  
     
70Q 
 
 
 
    
71R 
 
        
74E 
 
        
78Y 
 
  
  
  
81H   
   
  
85I   
   
  
86L   
   
  
89F   
   
  
90L           
 
Positions of the residues in the SLA binding pockets are shown. The first column (SLA position) is the 
residue and position in the SLA-DRB1*0201 protein sequence (Genbank:61652983). The next columns 
show, shaded in gray, the positions involved in pockets A through E that interact with specific positions 
of the peptides (peptide position). 
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Supplemental information for Chapter 3 
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Supplemental Text 1. Concatemer construct sequences. 
 
>Class I concatemer construct 
cggatctaccagattctggccatctacatcaccatcggcaagtgccccaagtactctctgctgaccgaagtggaaacatatggccccggacccggcac
cagtgccgatcagcagtctctgtacggacccggacccggggagatgaacgcccccaactatcactatctggccagctgcatgggactgatctacgac
accgtgaaccggacccaccagtacggcaccgagaagctgaccatcacatacgccttcgacgagcggcggaacaaatacgataccgtgcacgacc
ggaccccctatctgactgaagtggaaacttacgtgctgggacccggacccggcagcgtgaagaatggcacatacgactacggcaccatcaaggac
agaagcccctacaacgccgacacactgtgcatcggctatgggcccggacccgggggaatggtggatgggtggtacggctactgcaccgagctgaa
gctgagcgactatggacccggacccggcgtgtcagatggcggcccaaatctgtacgaaatctgccccaagctggccgagtacaagagctgcatcaa
ccggtgcttctaccaagtgtcccggcccatgtttctgtacggcgccaaagaagtggctctgagctacggacccggacccggcgaactggatgcccca
aactaccactacgatctgctggaaaatctgcaagcctacgccagccaaggcaccaagcggagctacaacaccgatctggaagctctgatggaaaac
atggacaaggccgtgaagctgtatctgagcaccgccagcagctggtcttacggacccggacccggcggaatgatcgacgggtggtatggatactga
tga 
 
>Class II concatemer construct 
acaagaggcgtgcagatcgccagcaacgagaacgtggaaaccatggacagcaacacactggaactgcggacatacgtgctgagcatcatcccca
gcggccctctgaaggccgagatcgcccagagactggaaagcgtgtacagatacggcttcgtggccaacttcagcatggaactgcccagcttcggcg
tgtccggctgcagaacattctttctgacacaaggcgctctgctgaacgacaagcacatcgaccccttcaagctgctgcagaatagccaagtggtgtctc
tgatgcggccctacgaggaactgcgcgagcagctgtccagcgtgtccagcttcgagcggttccaagacattctgatgcgcatgagcaagatgcagct
gggctccagcagcgagatgatgggcatgttcaatatgctgagcaccgtgctgggcgtgtccatcggcgacaagatcacattcgaggccaccggcaa
tctggtggtgccccggtacagatccaagtttctgctgatggacgctctgaagctgtccatcgaggaccctagctgcatgggactgatctacaaccggat
gggcaccgtgaccaccgaggccgcttttggactcgtgtgcttcgagcagatcactttcatgcaagctctgcagctgctgctggaagtggaaaaccaga
cttacgtgaacatcagcaacaccaacttcgccgctggccagagcgtggtgtccgtgaagctggtgcccagatacgcctttgccatggaacggaatgc
cggcagcggcatcatcatcagcgaagtgcacatctactatctggaaaaggccaacaagatcaagagcgagaaaacccacatccacatctttggcccc
ggacccggcatggccaatctgattctgcagatcggcaacatcatctccatctggatcagccactctatcgaggatctgatctttctggctcggagcgcac
tgattctgagaggcagcgtggcccacaagagctgtctgcccaccagacagatggtgcacgccatgagaaccatcggcacccaccctagctctagcg
cctccgtggtgtctgtgaaactggccggcaatagctctctgtgccccgtgtccacccggatctaccagattctggccatctacagcaccgtggcctcttc
tctggtgctcgtgtgatga 
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Supplemental Table 2. Low-resolution SLA-typing results. 
  
SLA class I SLA class II 
Group Pig SLA-1 SLA-2 SLA-3 DRB1 DQB1 DQA 
NV 413 08XX  0901-02  05XX,0602  07XX,10XX  0201,06XX  01XX,02XX 
 
414 08XX,15XX  12XX,16XX  0601,07XX  0401-02,0403-04  0202,0302-03  02XX 
Sham 419 08XX,15XX  05XX,16XX  07XX  0403-04,10XX  06XX,07XX  01XX 
 
420 08XX  0901-02,12XX  05XX,0601  0401-02,07XX  0201,0202 02XX 
 
421 08XX,12XX,1301  05XX,10XX  05XX,07XX  06XX,10XX  06XX,07XX  01XX 
 
422 08XX,15XX  12XX,16XX  0601,07XX  0401-02,0403-04  0202,0302-03 02XX 
 
423 08XX  0901-02,12XX  05XX,0601  0401-02,07XX  0201,0202 02XX 
 
424 08XX  12XX 0601 0401-02  0202 02XX 
 
425 12XX,1301 10XX 05XX  06XX,10XX  06XX,07XX  01XX  
 
426 08XX  05XX,12XX  0601,07XX  0401-02,10XX  0202,06XX  01XX,02XX 
PigMatrix-
EDV 
428 08XX  05XX,12XX  0601,07XX  0401-02,10XX  0202,06XX  01XX,02XX 
429 08XX,12XX,1301  0901-02,12XX  05XX,0602  06XX,10XX  06XX,07XX  01XX  
 
430 08XX  05XX,12XX  0601,07XX  0401-02,10XX  0202,06XX  01XX,02XX  
 
431 08XX,12XX,1301  05XX,10XX  05XX,07XX  06XX,10XX  06XX,07XX  01XX 
 
432 08XX  05XX,10XX  05XX,07XX  10XX  06XX 01XX  
 
433 08XX,12XX,1301  0901-02,12XX  05XX,0602  06XX,10XX  06XX,07XX  01XX  
 
434 04XX,08XX  04XX,12XX  04XX,0601  0401-02,09XX  0202,08XX  02XX,03XX  
FluSure 435 1103,12XX,1301  10XX,jh02  05XX  06XX  07XX  01XX  
 
436 08XX  05XX,12XX  05XX,0601  0401-02,10XX  0202,06XX  01XX,02XX  
 
437 12XX,1301  10XX 05XX  06XX  07XX  01XX  
 
438 08XX,12XX,1301  05XX,12XX  05XX,0601  0401-02,06XX  0202,07XX  01XX,02XX 
 
439 08XX  12XX  0601 0401-02  0202 02XX  
 
440 07XX,08XX  02XX,05XX  04XX,07XX  02XX,10XX  0201,06XX  01XX,02XX  
 
441 1103,12XX,1301  10XX,jh02  05XX  06XX  07XX  01XX  
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Supplemental information for Chapter 4 
Supplemental Table 1. EpiCC scores between HA sequences of IA00 H1γ FS vaccine virus and 
field viruses. 
 
 
Score 
Straina Shared (%)b 
Vaccine 
unique 
Strain 
unique 
Total 
EpiCC 
IA00 H1γ FS 0.118 (100) 0.000 0.000 0.118 
MN11 H1γ (P) 0.097 (82.2) 0.022 0.025 0.050 
IA92 H1α (P) 0.092 (78.0) 0.027 0.027 0.038 
OH10 H1γ (P) 0.091 (77.1) 0.028 0.028 0.036 
IA15 H1γ 0.088 (74.6) 0.030 0.031 0.026 
CA09 H1pdm (P) 0.087 (73.7) 0.032 0.031 0.023 
MN15 H1γ 0.085 (72.0) 0.034 0.033 0.018 
SH91 H1α 0.083 (70.3) 0.035 0.037 0.011 
IA04 H1β 0.079 (66.9) 0.040 0.039 0.000 
MN02 H1β (P)* 0.078 (66.1) 0.041 0.040 -0.002 
IA12 H1γ-2 0.071 (60.2) 0.048 0.045 -0.023 
IL08 H1α (PP)* 0.068 (57.6) 0.051 0.054 -0.038 
IA30 cH1 0.060 (50.8) 0.060 0.060 -0.060 
SD15 H1α 0.058 (49.2) 0.062 0.065 -0.068 
NC05 H1δ2 FS 0.053 (44.9) 0.066 0.069 -0.082 
NC05 H1δ2 0.053 (44.9) 0.066 0.069 -0.083 
OK08 H1δ1 FS 0.053 (44.9) 0.066 0.070 -0.083 
ON04 H1δ1 0.052 (44.1) 0.068 0.074 -0.090 
IL11 H1δ1 0.050 (42.4) 0.070 0.071 -0.091 
OK14 H1δ1 0.052 (44.1) 0.068 0.076 -0.092 
SD15 H1δ1 0.049 (41.5) 0.071 0.073 -0.095 
IA15 H1δ1 0.049 (41.5) 0.071 0.081 -0.103 
MN15b H1δ1 0.048 (40.7) 0.072 0.083 -0.107 
MN15a H1δ1 0.043 (36.4) 0.077 0.083 -0.117 
aFS γ-cluster vaccine strain was protective or partially protective against challenge with viruses 
annotated as (P) or (PP), respectively. Viruses used to set the thresholds are marked with an asterisk (*). 
bRatio of the score of shared epitopes relative to the baseline EpiCC scores expressed as percentage. 
Table is sorted by total EpiCC score. Strains below the total EpiCC score threshold associated with 
partial protection are shown in gray. 		
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Supplemental Fig. 1. Comparison of HA baseline EpiCC score by set of MHC alleles. 
 
 
Baseline EpiCC score of HA sequences of each virus (E(s,s)A) was determined using predictions for 
swine and human class I and II MHC alleles (SLA-I: 8 alleles, SLA-II: 5 alleles, HLA-I: 6 alleles, and 
HLA-II: 8 alleles). P-values of comparisons were calculated using one-tailed Wilcoxon matched-pairs 
signed rank test (**p<0.001, *p<0.05).  
 
 
**	
**	
*	
*	
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Supplemental Fig. 2. Comparison of scores of shared and unique epitopes across strains. 
 
 
Scores of shared, vaccine unique and strain unique HLA class I and II epitopes were determined for the 
comparison of HA sequences from vaccine viruses and field (challenge) strains. Note that y-axes show 
different scales. Solid connecting lines are included only for visualization purposes. P-values of 
comparisons were calculated using one-tailed Wilcoxon matched-pairs signed rank test (**p<0.001, 
*p<0.05). HA vaccine sequences had higher scores for shared epitopes with strains belonging to the 
same H1 cluster or the same HA lineage. Scores of class II shared epitopes were significantly higher 
than those of class I. Class II scores of unique epitopes were also higher for OK08 H1δ1 FS (vaccine 
unique) and NC05 H1δ2 FS (strain unique). In contrast, class I scores of IA00 H1γ FS vaccine unique 
epitopes were higher than those of class II, which is explained by the higher baseline EpiCC score of 
the vaccine. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the x-axis 
are described in detail in the legend below.  
 
*	
*	
**	 **	
**	**	
1:IA00 H1γ FS 4:OH10 H1γ  7:IA15 H1γ 10:SH91 H1α 13:SD15 H1α 16:NC05 H1δ2 19:IL11 H1δ1 22:IA15 H1δ1 
2:IA92 H1α  5:CA09 H1pdm  8:IA04 H1β 11:MN15 H1γ 14:IA30 cH1 17:OK08 H1δ1 FS 20:OK14 H1δ1 23:SD15 H1δ1 
3:MN11 H1γ  6:IA12 H1γ-2 9:MN02 H1β 12:IL08 H1α 15:NC05 H1δ2 FS 18:ON04 H1δ1 21:MN15a H1δ1 24:MN15b H1δ1 
Strain 
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Supplemental Fig. 3. Relationship between EpiCC scores and nucleotide identity. 
 
 
 
The second order polynomial relationship between class I (top), II (bottom) EpiCC scores, and 
nucleotide identity for each FS virus are shown. R2 of regression models are shown. H3N2, H4N6 and a 
random sequence were included in this analysis to represent the lower end of the identity range. Class I 
and II EpiCC scores correlated with identity between HA nucleotide sequences of vaccines and viral 
strains (r=0.89 – 0.90). However, their relationship was non linear; instead, it was second order 
polynomial (R2=0.93 – 0.98). EpiCC score was close to the lowest at approximately 50% identity. 
 
R2	=	0.97	
R2	=	0.93	
R2	=	0.98	
R2	=	0.96	
R2	=	0.96	
R2	=	0.96	
